<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308163</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-RAJ3</org_study_id>
    <nct_id>NCT02308163</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs</brief_title>
  <official_title>Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to verify the superiority of ASP015K alone or in combination
      with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in
      participants with rheumatoid arthritis (RA) who had an inadequate response to DMARDs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multi-center, randomized, placebo-controlled, double-blind, parallel-group,
      confirmatory study to evaluate the efficacy and safety of ASP015K alone or in combination
      with DMARDs in participants with RA who had an inadequate response to DMARDs.

      Etanercept was also administered as the reference drug in an open-label manner. The study
      drug was orally administered once daily (QD) after breakfast for 52 weeks. Etanercept was
      administered subcutaneously QD for 52 weeks. At Week 12, participants in the placebo group
      were switched to ASP015K.

      The dose of ASP015K to be started at Week 12 for the placebo group was determined randomly at
      baseline in advance and switched in a blinded manner.

      Participants in ASP015K group or placebo groups who had completed the study were eligible for
      participation in an open-label extension study (015K-CL-RAJ2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2014</start_date>
  <completion_date type="Actual">November 22, 2017</completion_date>
  <primary_completion_date type="Actual">January 23, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12</measure>
    <time_frame>Baseline and Week 12/early termination (ET)</time_frame>
    <description>The ACR20 response required that all criteria from (1) to (3) below be met.
Tender joint count (TJC) : ≥ 20% reduction compared with baseline.
Swollen joint count (SJC) : ≥ 20% reduction compared with baseline.
≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline
(3) ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, Subject's Global Assessment of Arthritis (SGA), Physician's Global Assessment of Arthritis (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR20-CRP Response Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The ACR20 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 20% reduction compared with baseline.
SJC : ≥ 20% reduction compared with baseline.
≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 50% (ACR50)-CRP Response at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The ACR50 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 50% reduction compared with baseline.
SJC : ≥ 50% reduction compared with baseline.
≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR50-CRP Response Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The ACR50 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 50% reduction compared with baseline.
SJC : ≥ 50% reduction compared with baseline.
≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 70% (ACR70)-CRP Response at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The ACR70 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 70% reduction compared with baseline.
SJC : ≥ 70% reduction compared with baseline.
≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR70-CRP Response Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The ACR70 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 70% reduction compared with baseline.
SJC : ≥ 70% reduction compared with baseline.
≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline DAS28-CRP Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-Erythrocyte Sedimentation Rate (ESR) at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-ESR Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC (68 Joints) at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC (68 Joints) Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Count (SJC) (66 Joints) at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC (66 Joints) Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP &lt; 2.6 at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP &lt; 2.6 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR &lt; 2.6 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR &lt; 2.6 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP &lt;= 3.2 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP &lt;= 3.2 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR &lt;= 3.2 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR &lt;= 3.2 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CRP at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>Higher CRP indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CRP Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>Higher CRP indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ESR at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>Higher ESR indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ESR Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>Higher ESR indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good EULAR Response Using DAS28-ESR at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good EULAR Response Using DAS28-ESR Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR / EULAR Remission at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).
Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR / EULAR Remission Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a VAS of 0 - 100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.
Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SDAI Remission Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDAI Score at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDAI Score Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Score &lt;= 2.8 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8. Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving CDAI Score &lt;= 2.8 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Arthritis (PGA) at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGA Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subject's SGA at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGA Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subject's Assessment of Pain at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subject's Assessment of Pain Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Withdrew Due to Lack of Efficacy</measure>
    <time_frame>Up to week 12</time_frame>
    <description>The number of participants who withdrew due to lack of efficacy up to week 12 was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI Through Week 52</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52</measure>
    <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52</measure>
    <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52</measure>
    <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Work Time Missed Through Week 52</measure>
    <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Impairment While Working at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Impairment While Working Through Week 52</measure>
    <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Overall Work Impairment at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52</measure>
    <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Activity Impairment at Week 12</measure>
    <time_frame>Baseline and Week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Activity Impairment Through Week 52</measure>
    <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events During the First 12 Weeks</measure>
    <time_frame>Week 0 to Week 12</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events From Week 12</measure>
    <time_frame>Week 12 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peficitinib 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peficitinib 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peficitinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Peficitinib 100 mg</arm_group_label>
    <arm_group_label>Peficitinib 150 mg</arm_group_label>
    <other_name>ASP015K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has RA diagnosed according to the 1987 American College of Rheumatology (ACR)
             criteria or the 2010 American College of Rheumatology/European League against
             Rheumatism (ACR/EULAR) criteria

          -  Subject who did not receive the following drugs, or received the drugs with stable
             dosage for at least 28 days prior to the baseline (start of treatment) for RA
             treatment:

               -  Non-steroidal anti-inflammatory drugs (NSAIDs; excluding topical formulations),
                  oral morphine or equivalent opioid analgesics (≤ 30 mg/day), acetaminophen, or
                  oral corticosteroids (≤ 10 mg/day in prednisolone equivalent)

          -  At screening subject has active RA as evidenced by both of the following:

               -  ≥ 6 tender/painful joints (using 68-joint assessment)

               -  ≥ 6 swollen joints (using 66-joint assessment)

          -  CRP &gt; 0.50 mg/dL at screening

          -  Subject meets the ACR 1991 Revised Criteria for the Classification of Global
             Functional Status in RA Class I, II or, III at screening.

          -  Inadequate responder to (including subjects who were intolerant of) at least one DMARD
             administered for at least 90 days prior to screening

        Exclusion Criteria:

          -  Subject has received a biologic DMARD within the specified period

          -  Subject has received etanercept

          -  Inadequate responder to at least 3 biologic DMARDs as determined by
             investigator/sub-investigator

          -  Subject has received intra-articular, intravenous, intramuscular or endorectal
             (excluding suppositories for anal diseases) corticosteroid within 28 days prior to
             baseline

          -  Subject has participated in any study of ASP015K and has received ASP015K or placebo

          -  Subject has received other investigational drugs within 90 days or within 5
             half-lives, whichever is longer, prior to baseline

          -  Subject has received plasma exchange therapy within 60 days prior to baseline

          -  Subject has undergone joint drainage, has received local anesthesia and nerve block,
             or has received articular cartilage protectant at the assessed joint within 28 days
             prior to baseline

          -  Subject has undergone surgery and has residual effects in the assessed joints at the
             discretion of investigator/sub-investigator, or is scheduled to undergo surgery that
             may affect the study evaluation of the assessed joints at the discretion of
             investigator/sub-investigator

          -  A diagnosis of inflammatory arthritis (psoriatic arthritis, ankylosing spondylitis,
             SLE, sarcoidosis, etc.) other than RA

          -  Any of the following laboratory values at screening:

               -  Hemoglobin &lt; 9.0 g/dL

               -  Absolute neutrophil count &lt; 1000/μL

               -  Absolute lymphocyte count &lt; 800/μL

               -  Platelet count &lt; 75000/μL

               -  ALT ≥ 2 ×ULN

               -  AST ≥ 2 × ULN

               -  Total bilirubin (TBL) ≥ 1.5 × ULN

               -  Estimated GFR ≤ 40 mL/min as measured by the MDRD method

               -  β-D-glucan &gt; ULN [in case of Japan: ≥ 11 pg/mL]

               -  Positive HBs antigen, HBc antibody, HBs antibody or HBV-DNA quantitation
                  (However, subject with negative HBs antigen and HBV-DNA quantitation, and
                  positive HBc antibody and/or HBs antibody is eligible if HBV-DNA is monitored by
                  HBV-DNA quantitation at every scheduled visit after initiation of study drug or
                  reference drug administration.)

               -  Positive HCV antibody

          -  Subject has a history of or concurrent active tuberculosis (TB)

          -  Subject has a history of or concurrent interstitial pneumonia and
             investigator/sub-investigator judges that it is inappropriate for the subject to
             participate in this study

          -  Subject has a history of or concurrent malignant tumor (except for successfully
             treated basal cell carcinoma)

          -  Subject has received live or live attenuated virus vaccination within 56 days prior to
             baseline. (Inactivated vaccines including influenza and pneumococcal vaccines are
             allowed.)

          -  Subject has a history of or concurrent demyelinating disorders

          -  Subject has any ongoing severe, progressive, or uncontrolled renal, hepatic,
             hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac,
             neurological, infectious, or autoimmune disease except for RA (excluding Sjogren's
             syndrome and chronic thyroiditis), or any ongoing illness which would make the subject
             unsuitable for the study as determined by the investigator/sub-investigator

          -  Subject has a history of clinically significant allergy. (Clinically significant
             allergy includes allergies such as systemic urticaria induced by specific antigens and
             drugs, anaphylaxis, and allergy associated with shock necessitating hospitalized
             treatment.)

          -  Subject has concurrent cardiac failure, defined as NYHA classification Class III or
             higher, or a history of it

          -  Subject has concurrent prolonged QT syndrome or a history of it. Subject has prolonged
             QT interval (defined as QTc ≥ 500 msec. Subject has QTc ≥ 500 msec at retest will be
             excluded) at screening

          -  Subject has a history of positive HIV infection

          -  Subject has congenital short QT syndrome or a history of it. Subject has shortened QT
             interval (defined as QTc &lt; 330 msec. Subject has QTc &lt; 330 msec at retest will be
             excluded) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JP00037</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00109</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00130</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00066</name>
      <address>
        <city>Okazaki</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00140</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00108</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00156</name>
      <address>
        <city>Toyota</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00068</name>
      <address>
        <city>Yatomi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00102</name>
      <address>
        <city>Kamagaya</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00127</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00115</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00138</name>
      <address>
        <city>Yotsukaido</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00120</name>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00040</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00119</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00071</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00097</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00106</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00033</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00026</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00090</name>
      <address>
        <city>Hakodate</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00125</name>
      <address>
        <city>Kushiro</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00001</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00002</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00003</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00031</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00038</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00114</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00158</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00056</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00069</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00113</name>
      <address>
        <city>Kakogawa</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00041</name>
      <address>
        <city>Kato</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00042</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00092</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00154</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00117</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00107</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00073</name>
      <address>
        <city>Koga</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00054</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00049</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00084</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00048</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00058</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00141</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00096</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00128</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00057</name>
      <address>
        <city>Tamana</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00004</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00027</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00036</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00105</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00151</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00050</name>
      <address>
        <city>Hyuga</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00162</name>
      <address>
        <city>Isehaya</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00101</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00103</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00153</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00094</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00025</name>
      <address>
        <city>Nagaoka</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00144</name>
      <address>
        <city>Shibata</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00064</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00051</name>
      <address>
        <city>Setouchi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00011</name>
      <address>
        <city>Hannan</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00134</name>
      <address>
        <city>Higashiosaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00078</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00137</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00070</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00086</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00061</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00075</name>
      <address>
        <city>Ureshino</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00126</name>
      <address>
        <city>Gyoda</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00007</name>
      <address>
        <city>Hiki</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00082</name>
      <address>
        <city>Iruma</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00060</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00161</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00062</name>
      <address>
        <city>Kawaguchi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00052</name>
      <address>
        <city>Sayama</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00008</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00133</name>
      <address>
        <city>Kakegawa</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00077</name>
      <address>
        <city>Kanuma</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00024</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00043</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00149</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00152</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00095</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00099</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00142</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00063</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00053</name>
      <address>
        <city>Kiyose</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00072</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00083</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00148</name>
      <address>
        <city>Ota</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00100</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00032</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00010</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00155</name>
      <address>
        <city>Nishimuro</city>
        <state>Wakayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00104</name>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00047</name>
      <address>
        <city>Shunan</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00018</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00020</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00035</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00059</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00067</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00076</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00131</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00164</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00013</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00014</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00015</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00016</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00055</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00065</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00074</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00093</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00022</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00046</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00123</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00159</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00023</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00122</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00080</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00098</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00112</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00147</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00017</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00118</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00150</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00157</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00089</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00135</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00139</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00504</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00510</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00505</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00506</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00508</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00501</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00502</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00503</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00509</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00511</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR00507</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00708</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00709</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00704</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00705</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00710</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00712</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00701</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00702</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00711</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TW00703</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=335</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <results_first_submitted>January 6, 2020</results_first_submitted>
  <results_first_submitted_qc>March 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2020</results_first_posted>
  <disposition_first_submitted>January 9, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 9, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 12, 2018</disposition_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>ASP015K</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02308163/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02308163/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with rheumatoid arthritis (RA) who had an inadequate response to disease-modifying antirheumatic drugs (DMARDs) were enrolled in 142 sites in Japan, 11 sites in Korea and 12 sites in Taiwan.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1:1:2 ratio to peficitinib 100 mg, 150 mg, placebo or etanercept groups at baseline. At week 12, participants in the placebo group were switched to receive either peficitinib at a dose of 100 mg or 150 mg. The dose of peficitinib administered to the placebo group from week 12 was determined in advance randomly.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peficitinib 100 mg</title>
          <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Peficitinib 150 mg</title>
          <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo / Peficitinib 100 mg</title>
          <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
        </group>
        <group group_id="P4">
          <title>Placebo / Peficitinib 150 mg</title>
          <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
        </group>
        <group group_id="P5">
          <title>Etanercept</title>
          <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not fulfill eligible criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lab data met discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set (SAF) was defined as all participants who received at least 1 dose of the study drug or reference drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Peficitinib 100 mg</title>
          <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Peficitinib 150 mg</title>
          <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Etanercept</title>
          <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="200"/>
            <count group_id="B4" value="101"/>
            <count group_id="B5" value="507"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="12.2"/>
                    <measurement group_id="B2" value="55" spread="12.8"/>
                    <measurement group_id="B3" value="55.5" spread="11.6"/>
                    <measurement group_id="B4" value="56.3" spread="11.7"/>
                    <measurement group_id="B5" value="55.3" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="507"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count (68 Joints)</title>
          <population>The full analysis set (FAS) consisted of all participants who were randomized and received at least 1 dose of the study drug or reference drug.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="9.4"/>
                    <measurement group_id="B2" value="15.4" spread="9.5"/>
                    <measurement group_id="B3" value="14.9" spread="9.3"/>
                    <measurement group_id="B4" value="16.2" spread="10.7"/>
                    <measurement group_id="B5" value="15.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count (66 Joints)</title>
          <population>FAS</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="6.3"/>
                    <measurement group_id="B2" value="12.8" spread="7.1"/>
                    <measurement group_id="B3" value="11.9" spread="6.8"/>
                    <measurement group_id="B4" value="12.9" spread="7.2"/>
                    <measurement group_id="B5" value="12.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject’s Global Assessment of Arthritis Pain</title>
          <description>The participants assessed his/her own pain severity on a Visual analog scale (VAS) from 0-100 mm on the questionnaire form. Higher scores indicated greater activity pain.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.31" spread="26.71"/>
                    <measurement group_id="B2" value="58.02" spread="25.66"/>
                    <measurement group_id="B3" value="55.79" spread="26.54"/>
                    <measurement group_id="B4" value="57.56" spread="25.07"/>
                    <measurement group_id="B5" value="56.9" spread="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject’s Global Assessment of Arthritis</title>
          <description>The participants assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher scores indicated greater activity impairment.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.54" spread="24.78"/>
                    <measurement group_id="B2" value="59.52" spread="25.73"/>
                    <measurement group_id="B3" value="57.52" spread="26.92"/>
                    <measurement group_id="B4" value="58.99" spread="25.7"/>
                    <measurement group_id="B5" value="58.22" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician’s Global Assessment of Arthritis</title>
          <description>The investigator assessed the participants’ disease activity on a VAS of 0-100 mm on the physician assessment table. Higher scores indicated greater activity impairment.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.21" spread="20.11"/>
                    <measurement group_id="B2" value="58.46" spread="19.35"/>
                    <measurement group_id="B3" value="58.17" spread="19.87"/>
                    <measurement group_id="B4" value="61.93" spread="19.35"/>
                    <measurement group_id="B5" value="59.39" spread="19.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire - Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI (range 0 – 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category had at least two questions. Within each category, participants reported the amount of difficulty they had in performing the specific question items. Higher HAQ-DI score indicated greater disease activity.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.92" spread="0.69"/>
                    <measurement group_id="B2" value="1.03" spread="0.67"/>
                    <measurement group_id="B3" value="1.03" spread="0.75"/>
                    <measurement group_id="B4" value="1" spread="0.66"/>
                    <measurement group_id="B5" value="1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <population>FAS</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.296" spread="2.566"/>
                    <measurement group_id="B2" value="2.561" spread="2.597"/>
                    <measurement group_id="B3" value="2.055" spread="2.144"/>
                    <measurement group_id="B4" value="2.258" spread="2.224"/>
                    <measurement group_id="B5" value="2.247" spread="2.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR)</title>
          <population>FAS</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="27.4"/>
                    <measurement group_id="B2" value="50.6" spread="29.7"/>
                    <measurement group_id="B3" value="47.4" spread="29.8"/>
                    <measurement group_id="B4" value="47.9" spread="27.6"/>
                    <measurement group_id="B5" value="48.6" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Biologic Disease-modifying Antirheumatic Drug-inadequate Response (DMARD-IR)</title>
          <description>For the participants whose &quot;Reactivity&quot; was selected as &quot;Inadequate Response&quot; or &quot;Unknown&quot;, &quot;Prior Biologic DMARD-IR&quot; was regarded as &quot;Yes&quot;, Otherwise &quot;No&quot;.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="471"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant DMARD at Baseline</title>
          <description>Concomitant DMARD at Baseline used at the initiation of treatment with the study drug or reference drug was regarded as &quot;Yes&quot;, Otherwise &quot;No&quot;.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study Region</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Japan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="415"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Korea</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Taiwan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12</title>
        <description>The ACR20 response required that all criteria from (1) to (3) below be met.
Tender joint count (TJC) : ≥ 20% reduction compared with baseline.
Swollen joint count (SJC) : ≥ 20% reduction compared with baseline.
≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline
(3) ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, Subject's Global Assessment of Arthritis (SGA), Physician's Global Assessment of Arthritis (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), C-Reactive Protein (CRP).</description>
        <time_frame>Baseline and Week 12/early termination (ET)</time_frame>
        <population>The analysis population consisted of the Full Analysis Set (FAS). Last observation carried forward (LOCF) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12</title>
          <description>The ACR20 response required that all criteria from (1) to (3) below be met.
Tender joint count (TJC) : ≥ 20% reduction compared with baseline.
Swollen joint count (SJC) : ≥ 20% reduction compared with baseline.
≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline
(3) ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, Subject's Global Assessment of Arthritis (SGA), Physician's Global Assessment of Arthritis (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), C-Reactive Protein (CRP).</description>
          <population>The analysis population consisted of the Full Analysis Set (FAS). Last observation carried forward (LOCF) was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7"/>
                    <measurement group_id="O2" value="57.7"/>
                    <measurement group_id="O3" value="74.5"/>
                    <measurement group_id="O4" value="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Closed testing procedure was used for multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>5.58</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: ACR20-CRP response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Closed testing procedure was used for multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.56</ci_lower_limit>
            <ci_upper_limit>12.20</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: ACR20-CRP response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR20-CRP Response Through Week 52</title>
        <description>The ACR20 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 20% reduction compared with baseline.
SJC : ≥ 20% reduction compared with baseline.
≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR20-CRP Response Through Week 52</title>
          <description>The ACR20 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 20% reduction compared with baseline.
SJC : ≥ 20% reduction compared with baseline.
≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="19.1"/>
                    <measurement group_id="O5" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="68.7"/>
                    <measurement group_id="O3" value="38.1"/>
                    <measurement group_id="O4" value="25.5"/>
                    <measurement group_id="O5" value="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="77.2"/>
                    <measurement group_id="O3" value="31.7"/>
                    <measurement group_id="O4" value="34.0"/>
                    <measurement group_id="O5" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5"/>
                    <measurement group_id="O2" value="79.6"/>
                    <measurement group_id="O3" value="58.5"/>
                    <measurement group_id="O4" value="61.7"/>
                    <measurement group_id="O5" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1"/>
                    <measurement group_id="O2" value="81.5"/>
                    <measurement group_id="O3" value="51.2"/>
                    <measurement group_id="O4" value="71.7"/>
                    <measurement group_id="O5" value="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="85.6"/>
                    <measurement group_id="O3" value="61.5"/>
                    <measurement group_id="O4" value="71.1"/>
                    <measurement group_id="O5" value="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3"/>
                    <measurement group_id="O2" value="87.6"/>
                    <measurement group_id="O3" value="60.0"/>
                    <measurement group_id="O4" value="67.4"/>
                    <measurement group_id="O5" value="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="88.4"/>
                    <measurement group_id="O3" value="63.9"/>
                    <measurement group_id="O4" value="73.3"/>
                    <measurement group_id="O5" value="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="90.7"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="76.7"/>
                    <measurement group_id="O5" value="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="90.7"/>
                    <measurement group_id="O3" value="67.6"/>
                    <measurement group_id="O4" value="83.3"/>
                    <measurement group_id="O5" value="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7"/>
                    <measurement group_id="O2" value="88.2"/>
                    <measurement group_id="O3" value="79.4"/>
                    <measurement group_id="O4" value="84.6"/>
                    <measurement group_id="O5" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3"/>
                    <measurement group_id="O2" value="90.5"/>
                    <measurement group_id="O3" value="73.5"/>
                    <measurement group_id="O4" value="82.1"/>
                    <measurement group_id="O5" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="90.1"/>
                    <measurement group_id="O3" value="79.4"/>
                    <measurement group_id="O4" value="81.6"/>
                    <measurement group_id="O5" value="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4"/>
                    <measurement group_id="O2" value="84.3"/>
                    <measurement group_id="O3" value="67.4"/>
                    <measurement group_id="O4" value="74.5"/>
                    <measurement group_id="O5" value="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50)-CRP Response at Week 12</title>
        <description>The ACR50 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 50% reduction compared with baseline.
SJC : ≥ 50% reduction compared with baseline.
≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50)-CRP Response at Week 12</title>
          <description>The ACR50 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 50% reduction compared with baseline.
SJC : ≥ 50% reduction compared with baseline.
≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
          <population>FAS. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="42.2"/>
                    <measurement group_id="O4" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.14</ci_lower_limit>
            <ci_upper_limit>10.75</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: ACR50-CRP response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.53</ci_lower_limit>
            <ci_upper_limit>17.50</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: ACR50-CRP response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR50-CRP Response Through Week 52</title>
        <description>The ACR50 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 50% reduction compared with baseline.
SJC : ≥ 50% reduction compared with baseline.
≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR50-CRP Response Through Week 52</title>
          <description>The ACR50 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 50% reduction compared with baseline.
SJC : ≥ 50% reduction compared with baseline.
≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="35.4"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="6.4"/>
                    <measurement group_id="O5" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="45.7"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="12.8"/>
                    <measurement group_id="O5" value="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0"/>
                    <measurement group_id="O2" value="45.2"/>
                    <measurement group_id="O3" value="31.7"/>
                    <measurement group_id="O4" value="25.5"/>
                    <measurement group_id="O5" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3"/>
                    <measurement group_id="O2" value="54.3"/>
                    <measurement group_id="O3" value="22.0"/>
                    <measurement group_id="O4" value="43.5"/>
                    <measurement group_id="O5" value="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="62.2"/>
                    <measurement group_id="O3" value="38.5"/>
                    <measurement group_id="O4" value="44.4"/>
                    <measurement group_id="O5" value="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="60.7"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="65.1"/>
                    <measurement group_id="O3" value="52.8"/>
                    <measurement group_id="O4" value="44.4"/>
                    <measurement group_id="O5" value="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2"/>
                    <measurement group_id="O2" value="68.6"/>
                    <measurement group_id="O3" value="47.2"/>
                    <measurement group_id="O4" value="44.2"/>
                    <measurement group_id="O5" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="69.8"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="52.4"/>
                    <measurement group_id="O5" value="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7"/>
                    <measurement group_id="O2" value="69.4"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="53.8"/>
                    <measurement group_id="O5" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="58.8"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3"/>
                    <measurement group_id="O2" value="75.3"/>
                    <measurement group_id="O3" value="47.1"/>
                    <measurement group_id="O4" value="65.8"/>
                    <measurement group_id="O5" value="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="41.9"/>
                    <measurement group_id="O4" value="55.3"/>
                    <measurement group_id="O5" value="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70)-CRP Response at Week 12</title>
        <description>The ACR70 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 70% reduction compared with baseline.
SJC : ≥ 70% reduction compared with baseline.
≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70)-CRP Response at Week 12</title>
          <description>The ACR70 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 70% reduction compared with baseline.
SJC : ≥ 70% reduction compared with baseline.
≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
          <population>FAS. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="13.5"/>
                    <measurement group_id="O3" value="27.5"/>
                    <measurement group_id="O4" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo. Difference vs. Peficitinib 100mg was not estimable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>39.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.29</ci_lower_limit>
            <ci_upper_limit>301.61</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: ACR70-CRP response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR70-CRP Response Through Week 52</title>
        <description>The ACR70 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 70% reduction compared with baseline.
SJC : ≥ 70% reduction compared with baseline.
≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR70-CRP Response Through Week 52</title>
          <description>The ACR70 response required that all criteria from (1) to (3) below be met.
TJC : ≥ 70% reduction compared with baseline.
SJC : ≥ 70% reduction compared with baseline.
≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="14.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="29.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="8.5"/>
                    <measurement group_id="O5" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="19.6"/>
                    <measurement group_id="O5" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="15.4"/>
                    <measurement group_id="O4" value="22.2"/>
                    <measurement group_id="O5" value="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="38.2"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="17.4"/>
                    <measurement group_id="O5" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="39.5"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="24.4"/>
                    <measurement group_id="O5" value="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="18.6"/>
                    <measurement group_id="O5" value="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="35.7"/>
                    <measurement group_id="O5" value="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7"/>
                    <measurement group_id="O2" value="49.4"/>
                    <measurement group_id="O3" value="41.2"/>
                    <measurement group_id="O4" value="28.2"/>
                    <measurement group_id="O5" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="51.2"/>
                    <measurement group_id="O3" value="32.4"/>
                    <measurement group_id="O4" value="38.5"/>
                    <measurement group_id="O5" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="48.1"/>
                    <measurement group_id="O3" value="38.2"/>
                    <measurement group_id="O4" value="42.1"/>
                    <measurement group_id="O5" value="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="42.2"/>
                    <measurement group_id="O3" value="34.9"/>
                    <measurement group_id="O4" value="34.0"/>
                    <measurement group_id="O5" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="1.20"/>
                    <measurement group_id="O2" value="-1.62" spread="1.41"/>
                    <measurement group_id="O3" value="-2.17" spread="1.14"/>
                    <measurement group_id="O4" value="-2.42" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.41</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: DAS28 Change = Treatment + Baseline DAS28 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-1.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.86</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: DAS28 Change = Treatment + Baseline DAS28 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline DAS28-CRP Through Week 52</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline DAS28-CRP Through Week 52</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="0.97"/>
                    <measurement group_id="O2" value="-1.29" spread="0.83"/>
                    <measurement group_id="O3" value="-0.49" spread="0.78"/>
                    <measurement group_id="O4" value="-0.56" spread="0.86"/>
                    <measurement group_id="O5" value="-1.89" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.24"/>
                    <measurement group_id="O2" value="-1.92" spread="0.96"/>
                    <measurement group_id="O3" value="-0.70" spread="1.02"/>
                    <measurement group_id="O4" value="-0.65" spread="1.00"/>
                    <measurement group_id="O5" value="-2.27" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" spread="1.34"/>
                    <measurement group_id="O2" value="-2.27" spread="1.12"/>
                    <measurement group_id="O3" value="-0.70" spread="1.23"/>
                    <measurement group_id="O4" value="-0.82" spread="1.15"/>
                    <measurement group_id="O5" value="-2.49" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="1.37"/>
                    <measurement group_id="O2" value="-2.40" spread="1.26"/>
                    <measurement group_id="O3" value="-1.60" spread="1.29"/>
                    <measurement group_id="O4" value="-1.92" spread="1.25"/>
                    <measurement group_id="O5" value="-2.61" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.41"/>
                    <measurement group_id="O2" value="-2.57" spread="1.20"/>
                    <measurement group_id="O3" value="-1.58" spread="1.42"/>
                    <measurement group_id="O4" value="-2.15" spread="1.22"/>
                    <measurement group_id="O5" value="-2.73" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.39"/>
                    <measurement group_id="O2" value="-2.68" spread="1.24"/>
                    <measurement group_id="O3" value="-1.60" spread="1.34"/>
                    <measurement group_id="O4" value="-2.28" spread="1.30"/>
                    <measurement group_id="O5" value="-2.79" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.37"/>
                    <measurement group_id="O2" value="-2.80" spread="1.27"/>
                    <measurement group_id="O3" value="-1.90" spread="1.50"/>
                    <measurement group_id="O4" value="-2.35" spread="1.31"/>
                    <measurement group_id="O5" value="-2.90" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.30"/>
                    <measurement group_id="O2" value="-2.77" spread="1.29"/>
                    <measurement group_id="O3" value="-1.98" spread="1.47"/>
                    <measurement group_id="O4" value="-2.22" spread="1.35"/>
                    <measurement group_id="O5" value="-2.94" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="1.34"/>
                    <measurement group_id="O2" value="-2.87" spread="1.22"/>
                    <measurement group_id="O3" value="-2.21" spread="1.40"/>
                    <measurement group_id="O4" value="-2.26" spread="1.35"/>
                    <measurement group_id="O5" value="-2.91" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="1.36"/>
                    <measurement group_id="O2" value="-2.88" spread="1.27"/>
                    <measurement group_id="O3" value="-2.17" spread="1.46"/>
                    <measurement group_id="O4" value="-2.47" spread="1.48"/>
                    <measurement group_id="O5" value="-2.99" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.34" spread="1.29"/>
                    <measurement group_id="O2" value="-2.86" spread="1.37"/>
                    <measurement group_id="O3" value="-2.39" spread="1.35"/>
                    <measurement group_id="O4" value="-2.47" spread="1.42"/>
                    <measurement group_id="O5" value="-2.97" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.31"/>
                    <measurement group_id="O2" value="-2.98" spread="1.27"/>
                    <measurement group_id="O3" value="-2.58" spread="1.32"/>
                    <measurement group_id="O4" value="-2.73" spread="1.29"/>
                    <measurement group_id="O5" value="-3.03" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="1.38"/>
                    <measurement group_id="O2" value="-2.99" spread="1.26"/>
                    <measurement group_id="O3" value="-2.51" spread="1.29"/>
                    <measurement group_id="O4" value="-2.73" spread="1.30"/>
                    <measurement group_id="O5" value="-3.04" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.63"/>
                    <measurement group_id="O2" value="-2.75" spread="1.36"/>
                    <measurement group_id="O3" value="-2.11" spread="1.59"/>
                    <measurement group_id="O4" value="-2.50" spread="1.41"/>
                    <measurement group_id="O5" value="-2.80" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-Erythrocyte Sedimentation Rate (ESR) at Week 12</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-Erythrocyte Sedimentation Rate (ESR) at Week 12</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="1.17"/>
                    <measurement group_id="O2" value="-1.60" spread="1.39"/>
                    <measurement group_id="O3" value="-2.24" spread="1.23"/>
                    <measurement group_id="O4" value="-2.51" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.38</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: DAS28 Change = Treatment + Baseline DAS28 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-1.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.96</ci_lower_limit>
            <ci_upper_limit>-1.31</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: DAS28 Change = Treatment + Baseline DAS28 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-ESR Through Week 52</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-ESR Through Week 52</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="0.94"/>
                    <measurement group_id="O2" value="-1.26" spread="0.84"/>
                    <measurement group_id="O3" value="-0.46" spread="0.74"/>
                    <measurement group_id="O4" value="-0.63" spread="0.87"/>
                    <measurement group_id="O5" value="-1.90" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="1.20"/>
                    <measurement group_id="O2" value="-1.96" spread="1.04"/>
                    <measurement group_id="O3" value="-0.68" spread="0.99"/>
                    <measurement group_id="O4" value="-0.57" spread="0.92"/>
                    <measurement group_id="O5" value="-2.33" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.33"/>
                    <measurement group_id="O2" value="-2.35" spread="1.21"/>
                    <measurement group_id="O3" value="-0.66" spread="1.18"/>
                    <measurement group_id="O4" value="-0.80" spread="1.13"/>
                    <measurement group_id="O5" value="-2.58" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.40"/>
                    <measurement group_id="O2" value="-2.50" spread="1.36"/>
                    <measurement group_id="O3" value="-1.53" spread="1.33"/>
                    <measurement group_id="O4" value="-1.84" spread="1.20"/>
                    <measurement group_id="O5" value="-2.68" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.44"/>
                    <measurement group_id="O2" value="-2.65" spread="1.29"/>
                    <measurement group_id="O3" value="-1.57" spread="1.43"/>
                    <measurement group_id="O4" value="-2.15" spread="1.20"/>
                    <measurement group_id="O5" value="-2.76" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.11" spread="1.47"/>
                    <measurement group_id="O2" value="-2.79" spread="1.39"/>
                    <measurement group_id="O3" value="-1.60" spread="1.37"/>
                    <measurement group_id="O4" value="-2.25" spread="1.16"/>
                    <measurement group_id="O5" value="-2.86" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="1.43"/>
                    <measurement group_id="O2" value="-2.87" spread="1.37"/>
                    <measurement group_id="O3" value="-1.94" spread="1.51"/>
                    <measurement group_id="O4" value="-2.31" spread="1.29"/>
                    <measurement group_id="O5" value="-2.97" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="1.41"/>
                    <measurement group_id="O2" value="-2.88" spread="1.41"/>
                    <measurement group_id="O3" value="-1.98" spread="1.46"/>
                    <measurement group_id="O4" value="-2.26" spread="1.44"/>
                    <measurement group_id="O5" value="-3.01" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.43"/>
                    <measurement group_id="O2" value="-3.00" spread="1.36"/>
                    <measurement group_id="O3" value="-2.18" spread="1.39"/>
                    <measurement group_id="O4" value="-2.28" spread="1.35"/>
                    <measurement group_id="O5" value="-3.00" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.44"/>
                    <measurement group_id="O2" value="-3.02" spread="1.38"/>
                    <measurement group_id="O3" value="-2.12" spread="1.44"/>
                    <measurement group_id="O4" value="-2.49" spread="1.60"/>
                    <measurement group_id="O5" value="-3.10" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.40" spread="1.39"/>
                    <measurement group_id="O2" value="-3.02" spread="1.51"/>
                    <measurement group_id="O3" value="-2.39" spread="1.34"/>
                    <measurement group_id="O4" value="-2.55" spread="1.38"/>
                    <measurement group_id="O5" value="-3.05" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="1.40"/>
                    <measurement group_id="O2" value="-3.09" spread="1.44"/>
                    <measurement group_id="O3" value="-2.67" spread="1.39"/>
                    <measurement group_id="O4" value="-2.79" spread="1.28"/>
                    <measurement group_id="O5" value="-3.16" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="1.48"/>
                    <measurement group_id="O2" value="-3.06" spread="1.40"/>
                    <measurement group_id="O3" value="-2.45" spread="1.30"/>
                    <measurement group_id="O4" value="-2.67" spread="1.23"/>
                    <measurement group_id="O5" value="-3.10" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.70"/>
                    <measurement group_id="O2" value="-2.81" spread="1.47"/>
                    <measurement group_id="O3" value="-2.06" spread="1.56"/>
                    <measurement group_id="O4" value="-2.44" spread="1.44"/>
                    <measurement group_id="O5" value="-2.86" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC (68 Joints) at Week 12</title>
        <description>The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC (68 Joints) at Week 12</title>
          <description>The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="9.2"/>
                    <measurement group_id="O2" value="-8.2" spread="8.8"/>
                    <measurement group_id="O3" value="-9.9" spread="8.0"/>
                    <measurement group_id="O4" value="-10.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: TJC68 Change = Treatment + Baseline TJC68 + the prior biologic - DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-6.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: TJC68 Change = Treatment + Baseline TJC68 + the prior biologic - DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC (68 Joints) Through Week 52</title>
        <description>The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC (68 Joints) Through Week 52</title>
          <description>The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="8.0"/>
                    <measurement group_id="O2" value="-5.4" spread="6.0"/>
                    <measurement group_id="O3" value="-3.9" spread="8.1"/>
                    <measurement group_id="O4" value="-4.3" spread="6.4"/>
                    <measurement group_id="O5" value="-8.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="7.6"/>
                    <measurement group_id="O2" value="-8.6" spread="7.1"/>
                    <measurement group_id="O3" value="-4.4" spread="8.4"/>
                    <measurement group_id="O4" value="-3.9" spread="8.3"/>
                    <measurement group_id="O5" value="-10.3" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="8.8"/>
                    <measurement group_id="O2" value="-10.3" spread="8.0"/>
                    <measurement group_id="O3" value="-5.0" spread="9.7"/>
                    <measurement group_id="O4" value="-5.5" spread="7.6"/>
                    <measurement group_id="O5" value="-11.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="9.2"/>
                    <measurement group_id="O2" value="-10.3" spread="8.8"/>
                    <measurement group_id="O3" value="-7.7" spread="10.2"/>
                    <measurement group_id="O4" value="-9.6" spread="7.5"/>
                    <measurement group_id="O5" value="-11.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="9.2"/>
                    <measurement group_id="O2" value="-11.3" spread="8.6"/>
                    <measurement group_id="O3" value="-8.1" spread="10.8"/>
                    <measurement group_id="O4" value="-10.3" spread="7.9"/>
                    <measurement group_id="O5" value="-12.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="9.4"/>
                    <measurement group_id="O2" value="-11.3" spread="9.7"/>
                    <measurement group_id="O3" value="-7.6" spread="9.9"/>
                    <measurement group_id="O4" value="-11.7" spread="7.9"/>
                    <measurement group_id="O5" value="-12.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="8.8"/>
                    <measurement group_id="O2" value="-12.0" spread="9.3"/>
                    <measurement group_id="O3" value="-8.4" spread="10.3"/>
                    <measurement group_id="O4" value="-11.5" spread="8.2"/>
                    <measurement group_id="O5" value="-12.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="8.5"/>
                    <measurement group_id="O2" value="-12.2" spread="8.6"/>
                    <measurement group_id="O3" value="-9.2" spread="10.3"/>
                    <measurement group_id="O4" value="-11.1" spread="8.5"/>
                    <measurement group_id="O5" value="-12.4" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="8.6"/>
                    <measurement group_id="O2" value="-11.7" spread="8.4"/>
                    <measurement group_id="O3" value="-10.1" spread="9.5"/>
                    <measurement group_id="O4" value="-11.5" spread="8.1"/>
                    <measurement group_id="O5" value="-12.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="8.5"/>
                    <measurement group_id="O2" value="-11.8" spread="8.8"/>
                    <measurement group_id="O3" value="-9.9" spread="9.6"/>
                    <measurement group_id="O4" value="-12.2" spread="8.4"/>
                    <measurement group_id="O5" value="-12.9" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="8.2"/>
                    <measurement group_id="O2" value="-12.0" spread="8.7"/>
                    <measurement group_id="O3" value="-10.7" spread="10.0"/>
                    <measurement group_id="O4" value="-12.5" spread="7.8"/>
                    <measurement group_id="O5" value="-12.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="7.1"/>
                    <measurement group_id="O2" value="-12.4" spread="9.5"/>
                    <measurement group_id="O3" value="-11.3" spread="9.6"/>
                    <measurement group_id="O4" value="-13.2" spread="7.7"/>
                    <measurement group_id="O5" value="-12.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="7.6"/>
                    <measurement group_id="O2" value="-12.8" spread="9.3"/>
                    <measurement group_id="O3" value="-11.4" spread="10.1"/>
                    <measurement group_id="O4" value="-12.9" spread="7.9"/>
                    <measurement group_id="O5" value="-12.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="9.7"/>
                    <measurement group_id="O2" value="-11.5" spread="9.9"/>
                    <measurement group_id="O3" value="-9.6" spread="10.7"/>
                    <measurement group_id="O4" value="-11.9" spread="8.5"/>
                    <measurement group_id="O5" value="-11.9" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Count (SJC) (66 Joints) at Week 12</title>
        <description>The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count (SJC) (66 Joints) at Week 12</title>
          <description>The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="6.0"/>
                    <measurement group_id="O2" value="-6.0" spread="6.4"/>
                    <measurement group_id="O3" value="-8.4" spread="5.9"/>
                    <measurement group_id="O4" value="-8.3" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: TJC68 Change = Treatment + Baseline TJC68 + the prior biologic - DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-3.9</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: TJC68 Change = Treatment + Baseline TJC68 + the prior biologic - DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC (66 Joints) Through Week 52</title>
        <description>The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Lacebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC (66 Joints) Through Week 52</title>
          <description>The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.
Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.9"/>
                    <measurement group_id="O2" value="-4.7" spread="4.2"/>
                    <measurement group_id="O3" value="-2.5" spread="6.0"/>
                    <measurement group_id="O4" value="-2.2" spread="4.5"/>
                    <measurement group_id="O5" value="-6.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="5.6"/>
                    <measurement group_id="O2" value="-7.1" spread="5.2"/>
                    <measurement group_id="O3" value="-2.8" spread="5.8"/>
                    <measurement group_id="O4" value="-3.4" spread="4.7"/>
                    <measurement group_id="O5" value="-7.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="5.8"/>
                    <measurement group_id="O2" value="-8.7" spread="6.0"/>
                    <measurement group_id="O3" value="-3.3" spread="6.7"/>
                    <measurement group_id="O4" value="-3.9" spread="5.6"/>
                    <measurement group_id="O5" value="-8.3" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="6.0"/>
                    <measurement group_id="O2" value="-8.7" spread="6.0"/>
                    <measurement group_id="O3" value="-6.4" spread="6.3"/>
                    <measurement group_id="O4" value="-6.3" spread="5.3"/>
                    <measurement group_id="O5" value="-8.7" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.3"/>
                    <measurement group_id="O2" value="-9.1" spread="6.2"/>
                    <measurement group_id="O3" value="-6.6" spread="6.4"/>
                    <measurement group_id="O4" value="-7.8" spread="6.9"/>
                    <measurement group_id="O5" value="-9.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="6.0"/>
                    <measurement group_id="O2" value="-9.7" spread="6.5"/>
                    <measurement group_id="O3" value="-6.5" spread="6.2"/>
                    <measurement group_id="O4" value="-8.2" spread="7.6"/>
                    <measurement group_id="O5" value="-9.1" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="5.6"/>
                    <measurement group_id="O2" value="-10.4" spread="5.7"/>
                    <measurement group_id="O3" value="-6.7" spread="7.5"/>
                    <measurement group_id="O4" value="-8.7" spread="7.4"/>
                    <measurement group_id="O5" value="-9.7" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="6.3"/>
                    <measurement group_id="O2" value="-10.4" spread="5.7"/>
                    <measurement group_id="O3" value="-5.9" spread="8.3"/>
                    <measurement group_id="O4" value="-8.2" spread="7.5"/>
                    <measurement group_id="O5" value="-9.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="6.1"/>
                    <measurement group_id="O2" value="-10.4" spread="6.1"/>
                    <measurement group_id="O3" value="-7.6" spread="7.1"/>
                    <measurement group_id="O4" value="-8.5" spread="7.7"/>
                    <measurement group_id="O5" value="-9.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="5.7"/>
                    <measurement group_id="O2" value="-10.4" spread="6.3"/>
                    <measurement group_id="O3" value="-7.6" spread="7.0"/>
                    <measurement group_id="O4" value="-9.1" spread="8.0"/>
                    <measurement group_id="O5" value="-10.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="5.5"/>
                    <measurement group_id="O2" value="-10.5" spread="6.2"/>
                    <measurement group_id="O3" value="-8.0" spread="8.0"/>
                    <measurement group_id="O4" value="-9.3" spread="8.0"/>
                    <measurement group_id="O5" value="-9.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="5.8"/>
                    <measurement group_id="O2" value="-10.8" spread="6.4"/>
                    <measurement group_id="O3" value="-8.0" spread="7.2"/>
                    <measurement group_id="O4" value="-9.1" spread="8.1"/>
                    <measurement group_id="O5" value="-9.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="5.9"/>
                    <measurement group_id="O2" value="-11.0" spread="6.0"/>
                    <measurement group_id="O3" value="-8.2" spread="8.7"/>
                    <measurement group_id="O4" value="-9.4" spread="8.0"/>
                    <measurement group_id="O5" value="-10.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="7.1"/>
                    <measurement group_id="O2" value="-10.0" spread="6.5"/>
                    <measurement group_id="O3" value="-6.7" spread="9.7"/>
                    <measurement group_id="O4" value="-8.6" spread="8.0"/>
                    <measurement group_id="O5" value="-9.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP &lt; 2.6 at Week 12</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP &lt; 2.6 at Week 12</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="34.7"/>
                    <measurement group_id="O4" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.31</ci_lower_limit>
            <ci_upper_limit>17.67</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: DAS28-CRP score &lt; 2.6 (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.76</ci_lower_limit>
            <ci_upper_limit>27.27</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: DAS28-CRP score &lt; 2.6 (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP &lt; 2.6 Through Week 52</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP &lt; 2.6 Through Week 52</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="9.3"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="37.0"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="4.3"/>
                    <measurement group_id="O5" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="39.8"/>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="23.4"/>
                    <measurement group_id="O5" value="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="51.1"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="32.6"/>
                    <measurement group_id="O5" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="51.7"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                    <measurement group_id="O2" value="55.1"/>
                    <measurement group_id="O3" value="34.1"/>
                    <measurement group_id="O4" value="41.3"/>
                    <measurement group_id="O5" value="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="37.8"/>
                    <measurement group_id="O4" value="37.8"/>
                    <measurement group_id="O5" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                    <measurement group_id="O2" value="54.7"/>
                    <measurement group_id="O3" value="43.2"/>
                    <measurement group_id="O4" value="39.5"/>
                    <measurement group_id="O5" value="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="53.5"/>
                    <measurement group_id="O3" value="36.8"/>
                    <measurement group_id="O4" value="45.2"/>
                    <measurement group_id="O5" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="57.6"/>
                    <measurement group_id="O3" value="48.6"/>
                    <measurement group_id="O4" value="41.0"/>
                    <measurement group_id="O5" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="51.4"/>
                    <measurement group_id="O4" value="56.4"/>
                    <measurement group_id="O5" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="45.7"/>
                    <measurement group_id="O4" value="55.3"/>
                    <measurement group_id="O5" value="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="59.4"/>
                    <measurement group_id="O3" value="41.9"/>
                    <measurement group_id="O4" value="51.1"/>
                    <measurement group_id="O5" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR &lt; 2.6 at Week 12</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR &lt; 2.6 at Week 12</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="11.7"/>
                    <measurement group_id="O3" value="17.8"/>
                    <measurement group_id="O4" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo. Difference vs. Peficitinib 100mg was not estimable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>21.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.83</ci_lower_limit>
            <ci_upper_limit>166.66</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: DAS28-ESR score &lt; 2.6 (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR &lt; 2.6 Through Week 52</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR &lt; 2.6 Through Week 52</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="11.9"/>
                    <measurement group_id="O4" value="14.9"/>
                    <measurement group_id="O5" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="14.6"/>
                    <measurement group_id="O4" value="19.6"/>
                    <measurement group_id="O5" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="15.4"/>
                    <measurement group_id="O4" value="17.8"/>
                    <measurement group_id="O5" value="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="34.8"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="21.7"/>
                    <measurement group_id="O5" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="19.4"/>
                    <measurement group_id="O4" value="24.4"/>
                    <measurement group_id="O5" value="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="41.2"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="18.6"/>
                    <measurement group_id="O5" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="44.2"/>
                    <measurement group_id="O3" value="32.4"/>
                    <measurement group_id="O4" value="28.6"/>
                    <measurement group_id="O5" value="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="35.3"/>
                    <measurement group_id="O4" value="28.2"/>
                    <measurement group_id="O5" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="39.3"/>
                    <measurement group_id="O3" value="37.1"/>
                    <measurement group_id="O4" value="38.5"/>
                    <measurement group_id="O5" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="34.6"/>
                    <measurement group_id="O3" value="29.4"/>
                    <measurement group_id="O4" value="28.9"/>
                    <measurement group_id="O5" value="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="28.7"/>
                    <measurement group_id="O3" value="26.2"/>
                    <measurement group_id="O4" value="27.7"/>
                    <measurement group_id="O5" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP &lt;= 3.2 at Week 12</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP &lt;= 3.2 at Week 12</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="40.2"/>
                    <measurement group_id="O3" value="53.5"/>
                    <measurement group_id="O4" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.74</ci_lower_limit>
            <ci_upper_limit>12.29</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: DAS28-CRP score ≤ 3.2 (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.57</ci_lower_limit>
            <ci_upper_limit>20.41</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: DAS28-CRP score ≤ 3.2 (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP &lt;= 3.2 Through Week 52</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP &lt;= 3.2 Through Week 52</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="21.0"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="4.3"/>
                    <measurement group_id="O5" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="40.8"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="12.8"/>
                    <measurement group_id="O5" value="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="55.4"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="10.6"/>
                    <measurement group_id="O5" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="44.7"/>
                    <measurement group_id="O5" value="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="67.4"/>
                    <measurement group_id="O3" value="45.2"/>
                    <measurement group_id="O4" value="47.8"/>
                    <measurement group_id="O5" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="74.2"/>
                    <measurement group_id="O3" value="35.0"/>
                    <measurement group_id="O4" value="62.2"/>
                    <measurement group_id="O5" value="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="76.4"/>
                    <measurement group_id="O3" value="41.5"/>
                    <measurement group_id="O4" value="63.0"/>
                    <measurement group_id="O5" value="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                    <measurement group_id="O2" value="70.9"/>
                    <measurement group_id="O3" value="51.4"/>
                    <measurement group_id="O4" value="55.6"/>
                    <measurement group_id="O5" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="75.6"/>
                    <measurement group_id="O3" value="56.8"/>
                    <measurement group_id="O4" value="67.4"/>
                    <measurement group_id="O5" value="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="57.9"/>
                    <measurement group_id="O4" value="71.4"/>
                    <measurement group_id="O5" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3"/>
                    <measurement group_id="O2" value="75.3"/>
                    <measurement group_id="O3" value="57.1"/>
                    <measurement group_id="O4" value="74.4"/>
                    <measurement group_id="O5" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9"/>
                    <measurement group_id="O2" value="81.0"/>
                    <measurement group_id="O3" value="60.0"/>
                    <measurement group_id="O4" value="79.5"/>
                    <measurement group_id="O5" value="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="84.0"/>
                    <measurement group_id="O3" value="54.3"/>
                    <measurement group_id="O4" value="81.6"/>
                    <measurement group_id="O5" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9"/>
                    <measurement group_id="O2" value="77.2"/>
                    <measurement group_id="O3" value="48.8"/>
                    <measurement group_id="O4" value="76.6"/>
                    <measurement group_id="O5" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR &lt;= 3.2 at Week 12</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR &lt;= 3.2 at Week 12</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="37.6"/>
                    <measurement group_id="O4" value="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>8.12</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: DAS28-ESR score ≤ 3.2 (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.19</param_value>
            <ci_percent>96</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.42</ci_lower_limit>
            <ci_upper_limit>19.63</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: DAS28-ESR score ≤ 3.2 (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR &lt;= 3.2 Through Week 52</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR &lt;= 3.2 Through Week 52</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.
DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="4.3"/>
                    <measurement group_id="O5" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="9.3"/>
                    <measurement group_id="O4" value="2.2"/>
                    <measurement group_id="O5" value="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="39.1"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="8.5"/>
                    <measurement group_id="O5" value="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="25.5"/>
                    <measurement group_id="O5" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="51.6"/>
                    <measurement group_id="O3" value="19.5"/>
                    <measurement group_id="O4" value="34.8"/>
                    <measurement group_id="O5" value="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="37.8"/>
                    <measurement group_id="O5" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                    <measurement group_id="O2" value="59.6"/>
                    <measurement group_id="O3" value="36.6"/>
                    <measurement group_id="O4" value="41.3"/>
                    <measurement group_id="O5" value="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="54.7"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="40.0"/>
                    <measurement group_id="O5" value="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="61.2"/>
                    <measurement group_id="O3" value="41.7"/>
                    <measurement group_id="O4" value="37.2"/>
                    <measurement group_id="O5" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="59.3"/>
                    <measurement group_id="O3" value="43.2"/>
                    <measurement group_id="O4" value="47.6"/>
                    <measurement group_id="O5" value="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="46.2"/>
                    <measurement group_id="O5" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="54.3"/>
                    <measurement group_id="O4" value="53.8"/>
                    <measurement group_id="O5" value="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="69.1"/>
                    <measurement group_id="O3" value="41.2"/>
                    <measurement group_id="O4" value="52.6"/>
                    <measurement group_id="O5" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="61.4"/>
                    <measurement group_id="O3" value="38.1"/>
                    <measurement group_id="O4" value="46.8"/>
                    <measurement group_id="O5" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CRP at Week 12</title>
        <description>Higher CRP indicates greater disease activity.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CRP at Week 12</title>
          <description>Higher CRP indicates greater disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="1.498"/>
                    <measurement group_id="O2" value="-1.056" spread="1.908"/>
                    <measurement group_id="O3" value="-1.734" spread="1.906"/>
                    <measurement group_id="O4" value="-1.207" spread="2.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS Mean</param_type>
            <param_value>-1.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.220</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.546</ci_lower_limit>
            <ci_upper_limit>-0.679</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: CRP Change = Treatment + Baseline CRP + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-1.677</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.221</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.114</ci_lower_limit>
            <ci_upper_limit>-1.241</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: CRP Change = Treatment + Baseline CRP + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CRP Through Week 52</title>
        <description>Higher CRP indicates greater disease activity.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CRP Through Week 52</title>
          <description>Higher CRP indicates greater disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.817" spread="1.566"/>
                    <measurement group_id="O2" value="-1.359" spread="1.575"/>
                    <measurement group_id="O3" value="0.013" spread="1.070"/>
                    <measurement group_id="O4" value="0.073" spread="1.643"/>
                    <measurement group_id="O5" value="-1.360" spread="1.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.967" spread="1.877"/>
                    <measurement group_id="O2" value="-1.664" spread="1.768"/>
                    <measurement group_id="O3" value="0.198" spread="1.662"/>
                    <measurement group_id="O4" value="-0.076" spread="0.930"/>
                    <measurement group_id="O5" value="-1.337" spread="1.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.045" spread="1.827"/>
                    <measurement group_id="O2" value="-1.810" spread="1.908"/>
                    <measurement group_id="O3" value="0.026" spread="1.852"/>
                    <measurement group_id="O4" value="-0.142" spread="1.076"/>
                    <measurement group_id="O5" value="-1.205" spread="2.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.083" spread="2.062"/>
                    <measurement group_id="O2" value="-1.849" spread="2.099"/>
                    <measurement group_id="O3" value="-0.802" spread="2.127"/>
                    <measurement group_id="O4" value="-1.180" spread="1.109"/>
                    <measurement group_id="O5" value="-1.383" spread="1.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.964" spread="2.551"/>
                    <measurement group_id="O2" value="-1.819" spread="2.156"/>
                    <measurement group_id="O3" value="-0.581" spread="2.471"/>
                    <measurement group_id="O4" value="-1.294" spread="1.152"/>
                    <measurement group_id="O5" value="-1.525" spread="1.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.225" spread="2.168"/>
                    <measurement group_id="O2" value="-1.824" spread="2.200"/>
                    <measurement group_id="O3" value="-0.434" spread="2.251"/>
                    <measurement group_id="O4" value="-1.318" spread="1.486"/>
                    <measurement group_id="O5" value="-1.473" spread="1.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.323" spread="1.976"/>
                    <measurement group_id="O2" value="-1.904" spread="2.197"/>
                    <measurement group_id="O3" value="-1.013" spread="2.247"/>
                    <measurement group_id="O4" value="-1.266" spread="1.635"/>
                    <measurement group_id="O5" value="-1.611" spread="2.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.200" spread="1.973"/>
                    <measurement group_id="O2" value="-1.979" spread="2.223"/>
                    <measurement group_id="O3" value="-1.239" spread="2.227"/>
                    <measurement group_id="O4" value="-0.975" spread="3.345"/>
                    <measurement group_id="O5" value="-1.593" spread="1.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.310" spread="1.874"/>
                    <measurement group_id="O2" value="-2.043" spread="2.202"/>
                    <measurement group_id="O3" value="-1.084" spread="2.460"/>
                    <measurement group_id="O4" value="-1.192" spread="1.453"/>
                    <measurement group_id="O5" value="-1.467" spread="2.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.199" spread="2.011"/>
                    <measurement group_id="O2" value="-2.019" spread="2.240"/>
                    <measurement group_id="O3" value="-1.325" spread="2.566"/>
                    <measurement group_id="O4" value="-1.232" spread="1.609"/>
                    <measurement group_id="O5" value="-1.594" spread="2.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.202" spread="1.961"/>
                    <measurement group_id="O2" value="-1.978" spread="2.221"/>
                    <measurement group_id="O3" value="-1.292" spread="2.366"/>
                    <measurement group_id="O4" value="-1.225" spread="1.729"/>
                    <measurement group_id="O5" value="-1.627" spread="1.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.964" spread="2.074"/>
                    <measurement group_id="O2" value="-1.833" spread="2.882"/>
                    <measurement group_id="O3" value="-1.610" spread="2.103"/>
                    <measurement group_id="O4" value="-1.407" spread="1.747"/>
                    <measurement group_id="O5" value="-1.611" spread="1.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.138" spread="2.056"/>
                    <measurement group_id="O2" value="-2.068" spread="2.228"/>
                    <measurement group_id="O3" value="-1.566" spread="2.034"/>
                    <measurement group_id="O4" value="-1.534" spread="1.589"/>
                    <measurement group_id="O5" value="-1.595" spread="1.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.949" spread="2.368"/>
                    <measurement group_id="O2" value="-1.832" spread="2.221"/>
                    <measurement group_id="O3" value="-0.797" spread="2.879"/>
                    <measurement group_id="O4" value="-0.987" spread="3.366"/>
                    <measurement group_id="O5" value="-1.326" spread="2.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ESR at Week 12</title>
        <description>Higher ESR indicates greater disease activity.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ESR at Week 12</title>
          <description>Higher ESR indicates greater disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>mm/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="17.82"/>
                    <measurement group_id="O2" value="-12.96" spread="21.51"/>
                    <measurement group_id="O3" value="-23.92" spread="21.26"/>
                    <measurement group_id="O4" value="-20.92" spread="21.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-10.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.95</ci_lower_limit>
            <ci_upper_limit>-5.84</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: ESR Change = Treatment + Baseline ESR + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-21.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.01</ci_lower_limit>
            <ci_upper_limit>-16.27</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: ESR Change = Treatment + Baseline ESR + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ESR Through Week 52</title>
        <description>Higher ESR indicates greater disease activity.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ESR Through Week 52</title>
          <description>Higher ESR indicates greater disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>mm/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.98" spread="15.44"/>
                    <measurement group_id="O2" value="-14.99" spread="15.90"/>
                    <measurement group_id="O3" value="-0.63" spread="11.77"/>
                    <measurement group_id="O4" value="-3.87" spread="12.99"/>
                    <measurement group_id="O5" value="-19.20" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.27" spread="19.29"/>
                    <measurement group_id="O2" value="-21.59" spread="19.81"/>
                    <measurement group_id="O3" value="-0.95" spread="12.47"/>
                    <measurement group_id="O4" value="-2.07" spread="14.31"/>
                    <measurement group_id="O5" value="-20.88" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.49" spread="21.25"/>
                    <measurement group_id="O2" value="-25.26" spread="21.22"/>
                    <measurement group_id="O3" value="-2.62" spread="18.31"/>
                    <measurement group_id="O4" value="-4.43" spread="17.07"/>
                    <measurement group_id="O5" value="-21.74" spread="20.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.34" spread="20.98"/>
                    <measurement group_id="O2" value="-28.32" spread="21.66"/>
                    <measurement group_id="O3" value="-11.76" spread="19.87"/>
                    <measurement group_id="O4" value="-16.89" spread="17.70"/>
                    <measurement group_id="O5" value="-22.05" spread="19.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.77" spread="21.88"/>
                    <measurement group_id="O2" value="-27.34" spread="21.95"/>
                    <measurement group_id="O3" value="-12.69" spread="23.03"/>
                    <measurement group_id="O4" value="-20.62" spread="17.65"/>
                    <measurement group_id="O5" value="-21.91" spread="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.61" spread="22.60"/>
                    <measurement group_id="O2" value="-27.02" spread="26.00"/>
                    <measurement group_id="O3" value="-13.18" spread="21.90"/>
                    <measurement group_id="O4" value="-20.04" spread="18.45"/>
                    <measurement group_id="O5" value="-22.20" spread="23.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.47" spread="21.90"/>
                    <measurement group_id="O2" value="-27.21" spread="23.97"/>
                    <measurement group_id="O3" value="-16.29" spread="17.77"/>
                    <measurement group_id="O4" value="-18.02" spread="24.26"/>
                    <measurement group_id="O5" value="-23.52" spread="22.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.35" spread="23.09"/>
                    <measurement group_id="O2" value="-27.02" spread="23.81"/>
                    <measurement group_id="O3" value="-19.54" spread="21.98"/>
                    <measurement group_id="O4" value="-19.93" spread="25.80"/>
                    <measurement group_id="O5" value="-24.75" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.67" spread="23.77"/>
                    <measurement group_id="O2" value="-29.50" spread="25.26"/>
                    <measurement group_id="O3" value="-19.65" spread="22.64"/>
                    <measurement group_id="O4" value="-21.99" spread="21.52"/>
                    <measurement group_id="O5" value="-24.66" spread="22.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.74" spread="25.65"/>
                    <measurement group_id="O2" value="-29.79" spread="24.00"/>
                    <measurement group_id="O3" value="-19.45" spread="23.06"/>
                    <measurement group_id="O4" value="-21.71" spread="25.48"/>
                    <measurement group_id="O5" value="-25.87" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.77" spread="25.35"/>
                    <measurement group_id="O2" value="-29.07" spread="24.47"/>
                    <measurement group_id="O3" value="-21.43" spread="24.12"/>
                    <measurement group_id="O4" value="-22.31" spread="23.12"/>
                    <measurement group_id="O5" value="-25.73" spread="21.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.43" spread="25.70"/>
                    <measurement group_id="O2" value="-28.70" spread="24.69"/>
                    <measurement group_id="O3" value="-23.40" spread="23.87"/>
                    <measurement group_id="O4" value="-25.66" spread="22.30"/>
                    <measurement group_id="O5" value="-25.98" spread="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.77" spread="26.05"/>
                    <measurement group_id="O2" value="-28.59" spread="24.97"/>
                    <measurement group_id="O3" value="-21.03" spread="19.81"/>
                    <measurement group_id="O4" value="-23.24" spread="24.28"/>
                    <measurement group_id="O5" value="-24.23" spread="21.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.94" spread="27.20"/>
                    <measurement group_id="O2" value="-26.15" spread="25.02"/>
                    <measurement group_id="O3" value="-15.37" spread="24.27"/>
                    <measurement group_id="O4" value="-18.61" spread="27.67"/>
                    <measurement group_id="O5" value="-20.75" spread="26.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12</title>
        <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12</title>
          <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="38.6"/>
                    <measurement group_id="O3" value="51.5"/>
                    <measurement group_id="O4" value="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.98</ci_lower_limit>
            <ci_upper_limit>14.83</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.91</ci_lower_limit>
            <ci_upper_limit>24.03</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52</title>
        <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52</title>
          <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1"/>
                    <measurement group_id="O2" value="39.8"/>
                    <measurement group_id="O3" value="11.9"/>
                    <measurement group_id="O4" value="6.4"/>
                    <measurement group_id="O5" value="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                    <measurement group_id="O2" value="53.3"/>
                    <measurement group_id="O3" value="12.2"/>
                    <measurement group_id="O4" value="8.5"/>
                    <measurement group_id="O5" value="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4"/>
                    <measurement group_id="O2" value="60.2"/>
                    <measurement group_id="O3" value="34.1"/>
                    <measurement group_id="O4" value="40.4"/>
                    <measurement group_id="O5" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="65.2"/>
                    <measurement group_id="O3" value="46.3"/>
                    <measurement group_id="O4" value="43.5"/>
                    <measurement group_id="O5" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="71.9"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="57.8"/>
                    <measurement group_id="O5" value="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="74.2"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="58.7"/>
                    <measurement group_id="O5" value="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                    <measurement group_id="O2" value="68.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="46.7"/>
                    <measurement group_id="O5" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="74.4"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="62.8"/>
                    <measurement group_id="O5" value="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7"/>
                    <measurement group_id="O2" value="75.6"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7"/>
                    <measurement group_id="O2" value="74.1"/>
                    <measurement group_id="O3" value="55.9"/>
                    <measurement group_id="O4" value="71.8"/>
                    <measurement group_id="O5" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="79.8"/>
                    <measurement group_id="O3" value="55.9"/>
                    <measurement group_id="O4" value="79.5"/>
                    <measurement group_id="O5" value="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="81.5"/>
                    <measurement group_id="O3" value="52.9"/>
                    <measurement group_id="O4" value="78.9"/>
                    <measurement group_id="O5" value="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="75.2"/>
                    <measurement group_id="O3" value="47.6"/>
                    <measurement group_id="O4" value="72.3"/>
                    <measurement group_id="O5" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12</title>
        <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12</title>
          <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="75.2"/>
                    <measurement group_id="O3" value="92.1"/>
                    <measurement group_id="O4" value="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.38</ci_lower_limit>
            <ci_upper_limit>8.04</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good or Moderate Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald’s chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>16.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.31</ci_lower_limit>
            <ci_upper_limit>38.51</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good or Moderate Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52</title>
        <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52</title>
          <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="72.0"/>
                    <measurement group_id="O3" value="31.0"/>
                    <measurement group_id="O4" value="40.4"/>
                    <measurement group_id="O5" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="86.7"/>
                    <measurement group_id="O3" value="47.6"/>
                    <measurement group_id="O4" value="40.4"/>
                    <measurement group_id="O5" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="94.6"/>
                    <measurement group_id="O3" value="41.5"/>
                    <measurement group_id="O4" value="48.9"/>
                    <measurement group_id="O5" value="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7"/>
                    <measurement group_id="O2" value="92.5"/>
                    <measurement group_id="O3" value="73.2"/>
                    <measurement group_id="O4" value="85.1"/>
                    <measurement group_id="O5" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3"/>
                    <measurement group_id="O2" value="96.7"/>
                    <measurement group_id="O3" value="78.0"/>
                    <measurement group_id="O4" value="91.3"/>
                    <measurement group_id="O5" value="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1"/>
                    <measurement group_id="O2" value="96.6"/>
                    <measurement group_id="O3" value="71.8"/>
                    <measurement group_id="O4" value="91.1"/>
                    <measurement group_id="O5" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2"/>
                    <measurement group_id="O2" value="95.5"/>
                    <measurement group_id="O3" value="80.0"/>
                    <measurement group_id="O4" value="87.0"/>
                    <measurement group_id="O5" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="96.5"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="82.2"/>
                    <measurement group_id="O5" value="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3"/>
                    <measurement group_id="O2" value="96.5"/>
                    <measurement group_id="O3" value="86.1"/>
                    <measurement group_id="O4" value="86.0"/>
                    <measurement group_id="O5" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3"/>
                    <measurement group_id="O2" value="96.5"/>
                    <measurement group_id="O3" value="86.5"/>
                    <measurement group_id="O4" value="85.7"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="94.1"/>
                    <measurement group_id="O3" value="88.2"/>
                    <measurement group_id="O4" value="87.2"/>
                    <measurement group_id="O5" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5"/>
                    <measurement group_id="O2" value="97.6"/>
                    <measurement group_id="O3" value="94.1"/>
                    <measurement group_id="O4" value="89.7"/>
                    <measurement group_id="O5" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                    <measurement group_id="O2" value="98.8"/>
                    <measurement group_id="O3" value="94.1"/>
                    <measurement group_id="O4" value="92.1"/>
                    <measurement group_id="O5" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2"/>
                    <measurement group_id="O2" value="93.1"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="85.1"/>
                    <measurement group_id="O5" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good EULAR Response Using DAS28-ESR at Week 12</title>
        <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good EULAR Response Using DAS28-ESR at Week 12</title>
          <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="36.6"/>
                    <measurement group_id="O4" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald's chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>12.08</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald's chi-squared test</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>11.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.07</ci_lower_limit>
            <ci_upper_limit>29.74</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good EULAR Response Using DAS28-ESR Through Week 52</title>
        <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good EULAR Response Using DAS28-ESR Through Week 52</title>
          <description>Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.2"/>
                    <measurement group_id="O5" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="9.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="38.0"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2"/>
                    <measurement group_id="O2" value="40.2"/>
                    <measurement group_id="O3" value="22.0"/>
                    <measurement group_id="O4" value="21.7"/>
                    <measurement group_id="O5" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="51.6"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="31.1"/>
                    <measurement group_id="O5" value="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="21.1"/>
                    <measurement group_id="O4" value="34.1"/>
                    <measurement group_id="O5" value="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="59.6"/>
                    <measurement group_id="O3" value="35.0"/>
                    <measurement group_id="O4" value="37.8"/>
                    <measurement group_id="O5" value="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="54.7"/>
                    <measurement group_id="O3" value="37.1"/>
                    <measurement group_id="O4" value="36.4"/>
                    <measurement group_id="O5" value="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="59.3"/>
                    <measurement group_id="O3" value="41.7"/>
                    <measurement group_id="O4" value="43.9"/>
                    <measurement group_id="O5" value="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="48.5"/>
                    <measurement group_id="O4" value="43.6"/>
                    <measurement group_id="O5" value="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="52.9"/>
                    <measurement group_id="O4" value="52.6"/>
                    <measurement group_id="O5" value="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="69.1"/>
                    <measurement group_id="O3" value="39.4"/>
                    <measurement group_id="O4" value="48.6"/>
                    <measurement group_id="O5" value="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="61.4"/>
                    <measurement group_id="O3" value="36.6"/>
                    <measurement group_id="O4" value="43.5"/>
                    <measurement group_id="O5" value="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR at Week 12</title>
        <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR at Week 12</title>
          <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8"/>
                    <measurement group_id="O2" value="69.6"/>
                    <measurement group_id="O3" value="88.1"/>
                    <measurement group_id="O4" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald's chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.11</ci_lower_limit>
            <ci_upper_limit>6.93</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good or Moderate Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Wald's chi-squared test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>13.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.39</ci_lower_limit>
            <ci_upper_limit>29.17</ci_upper_limit>
            <estimate_desc>Based on logistic regression model: Good or Moderate Response (responder, non-responder) = Treatment + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR Through Week 52</title>
        <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR Through Week 52</title>
          <description>Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline &gt; 0.6, or DAS28 after treatment &gt; 5.1 and improvement from baseline &gt; 1.2.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="65.0"/>
                    <measurement group_id="O3" value="31.0"/>
                    <measurement group_id="O4" value="23.9"/>
                    <measurement group_id="O5" value="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3"/>
                    <measurement group_id="O2" value="84.7"/>
                    <measurement group_id="O3" value="45.2"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8"/>
                    <measurement group_id="O2" value="90.2"/>
                    <measurement group_id="O3" value="39.0"/>
                    <measurement group_id="O4" value="43.5"/>
                    <measurement group_id="O5" value="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3"/>
                    <measurement group_id="O2" value="88.0"/>
                    <measurement group_id="O3" value="73.2"/>
                    <measurement group_id="O4" value="76.1"/>
                    <measurement group_id="O5" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                    <measurement group_id="O2" value="96.7"/>
                    <measurement group_id="O3" value="72.5"/>
                    <measurement group_id="O4" value="86.7"/>
                    <measurement group_id="O5" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="95.5"/>
                    <measurement group_id="O3" value="73.7"/>
                    <measurement group_id="O4" value="90.9"/>
                    <measurement group_id="O5" value="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3"/>
                    <measurement group_id="O2" value="92.1"/>
                    <measurement group_id="O3" value="77.5"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1"/>
                    <measurement group_id="O2" value="94.2"/>
                    <measurement group_id="O3" value="77.1"/>
                    <measurement group_id="O4" value="86.4"/>
                    <measurement group_id="O5" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5"/>
                    <measurement group_id="O2" value="95.3"/>
                    <measurement group_id="O3" value="85.7"/>
                    <measurement group_id="O4" value="83.3"/>
                    <measurement group_id="O5" value="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                    <measurement group_id="O2" value="95.3"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="85.4"/>
                    <measurement group_id="O5" value="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7"/>
                    <measurement group_id="O2" value="92.9"/>
                    <measurement group_id="O3" value="84.8"/>
                    <measurement group_id="O4" value="87.2"/>
                    <measurement group_id="O5" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5"/>
                    <measurement group_id="O2" value="95.2"/>
                    <measurement group_id="O3" value="88.2"/>
                    <measurement group_id="O4" value="89.5"/>
                    <measurement group_id="O5" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5"/>
                    <measurement group_id="O2" value="97.5"/>
                    <measurement group_id="O3" value="84.8"/>
                    <measurement group_id="O4" value="89.2"/>
                    <measurement group_id="O5" value="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5"/>
                    <measurement group_id="O2" value="94.1"/>
                    <measurement group_id="O3" value="75.6"/>
                    <measurement group_id="O4" value="82.6"/>
                    <measurement group_id="O5" value="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR / EULAR Remission at Week 12</title>
        <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).
Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR / EULAR Remission at Week 12</title>
          <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).
Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR / EULAR Remission Through Week 52</title>
        <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a VAS of 0 - 100 mm).</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR / EULAR Remission Through Week 52</title>
          <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a VAS of 0 - 100 mm).</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="2.3"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="4.3"/>
                    <measurement group_id="O5" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="8.9"/>
                    <measurement group_id="O5" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="18.0"/>
                    <measurement group_id="O3" value="9.8"/>
                    <measurement group_id="O4" value="10.9"/>
                    <measurement group_id="O5" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="20.9"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="11.1"/>
                    <measurement group_id="O5" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="7.0"/>
                    <measurement group_id="O5" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="19.8"/>
                    <measurement group_id="O3" value="7.9"/>
                    <measurement group_id="O4" value="14.3"/>
                    <measurement group_id="O5" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="7.7"/>
                    <measurement group_id="O5" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="25.7"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="22.9"/>
                    <measurement group_id="O4" value="10.5"/>
                    <measurement group_id="O5" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="20.9"/>
                    <measurement group_id="O4" value="8.5"/>
                    <measurement group_id="O5" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission at Week 12</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.
Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission at Week 12</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.
Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="8.9"/>
                    <measurement group_id="O4" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SDAI Remission Through Week 52</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SDAI Remission Through Week 52</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="9.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="15.1"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="8.5"/>
                    <measurement group_id="O5" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="15.2"/>
                    <measurement group_id="O5" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="18.0"/>
                    <measurement group_id="O3" value="10.0"/>
                    <measurement group_id="O4" value="17.8"/>
                    <measurement group_id="O5" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="17.1"/>
                    <measurement group_id="O4" value="17.4"/>
                    <measurement group_id="O5" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="13.5"/>
                    <measurement group_id="O4" value="13.3"/>
                    <measurement group_id="O5" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="18.9"/>
                    <measurement group_id="O4" value="4.7"/>
                    <measurement group_id="O5" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="19.0"/>
                    <measurement group_id="O5" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="38.8"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="38.1"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="25.6"/>
                    <measurement group_id="O5" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="29.6"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="21.1"/>
                    <measurement group_id="O5" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="18.6"/>
                    <measurement group_id="O4" value="17.0"/>
                    <measurement group_id="O5" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDAI Score at Week 12</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDAI Score at Week 12</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.22" spread="14.11"/>
                    <measurement group_id="O2" value="-16.08" spread="14.37"/>
                    <measurement group_id="O3" value="-20.93" spread="11.32"/>
                    <measurement group_id="O4" value="-21.94" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS Mean</param_type>
            <param_value>-9.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.66</ci_lower_limit>
            <ci_upper_limit>-6.22</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SDAI Change = Treatment + Baseline SDAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>-14.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.71</ci_lower_limit>
            <ci_upper_limit>-11.15</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SDAI Change = Treatment + Baseline SDAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDAI Score Through Week 52</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDAI Score Through Week 52</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.
SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.83" spread="9.97"/>
                    <measurement group_id="O2" value="-12.78" spread="9.06"/>
                    <measurement group_id="O3" value="-5.57" spread="9.50"/>
                    <measurement group_id="O4" value="-7.21" spread="9.35"/>
                    <measurement group_id="O5" value="-17.09" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.71" spread="12.53"/>
                    <measurement group_id="O2" value="-18.66" spread="9.73"/>
                    <measurement group_id="O3" value="-7.07" spread="12.26"/>
                    <measurement group_id="O4" value="-8.43" spread="11.37"/>
                    <measurement group_id="O5" value="-20.64" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.59" spread="13.47"/>
                    <measurement group_id="O2" value="-21.62" spread="11.48"/>
                    <measurement group_id="O3" value="-7.48" spread="14.80"/>
                    <measurement group_id="O4" value="-10.18" spread="11.82"/>
                    <measurement group_id="O5" value="-22.54" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.25" spread="13.76"/>
                    <measurement group_id="O2" value="-21.90" spread="12.19"/>
                    <measurement group_id="O3" value="-15.20" spread="14.25"/>
                    <measurement group_id="O4" value="-18.90" spread="12.08"/>
                    <measurement group_id="O5" value="-23.46" spread="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.47" spread="14.16"/>
                    <measurement group_id="O2" value="-23.37" spread="11.94"/>
                    <measurement group_id="O3" value="-15.67" spread="15.41"/>
                    <measurement group_id="O4" value="-20.61" spread="12.44"/>
                    <measurement group_id="O5" value="-24.44" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.14" spread="13.96"/>
                    <measurement group_id="O2" value="-24.40" spread="12.00"/>
                    <measurement group_id="O3" value="-16.13" spread="14.40"/>
                    <measurement group_id="O4" value="-22.25" spread="13.22"/>
                    <measurement group_id="O5" value="-24.78" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.29" spread="12.71"/>
                    <measurement group_id="O2" value="-25.29" spread="12.32"/>
                    <measurement group_id="O3" value="-17.75" spread="15.21"/>
                    <measurement group_id="O4" value="-22.74" spread="13.00"/>
                    <measurement group_id="O5" value="-25.70" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.72" spread="12.82"/>
                    <measurement group_id="O2" value="-25.28" spread="12.07"/>
                    <measurement group_id="O3" value="-17.71" spread="15.34"/>
                    <measurement group_id="O4" value="-21.14" spread="14.69"/>
                    <measurement group_id="O5" value="-25.84" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.34" spread="12.65"/>
                    <measurement group_id="O2" value="-25.62" spread="11.95"/>
                    <measurement group_id="O3" value="-20.57" spread="14.03"/>
                    <measurement group_id="O4" value="-22.02" spread="13.54"/>
                    <measurement group_id="O5" value="-25.77" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.55" spread="13.04"/>
                    <measurement group_id="O2" value="-25.78" spread="12.54"/>
                    <measurement group_id="O3" value="-20.34" spread="14.90"/>
                    <measurement group_id="O4" value="-23.09" spread="14.63"/>
                    <measurement group_id="O5" value="-26.46" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.54" spread="12.22"/>
                    <measurement group_id="O2" value="-25.82" spread="12.92"/>
                    <measurement group_id="O3" value="-22.65" spread="13.74"/>
                    <measurement group_id="O4" value="-23.23" spread="14.31"/>
                    <measurement group_id="O5" value="-26.17" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.11" spread="12.13"/>
                    <measurement group_id="O2" value="-26.33" spread="12.58"/>
                    <measurement group_id="O3" value="-23.21" spread="13.47"/>
                    <measurement group_id="O4" value="-24.61" spread="13.35"/>
                    <measurement group_id="O5" value="-26.57" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.19" spread="12.83"/>
                    <measurement group_id="O2" value="-26.99" spread="12.52"/>
                    <measurement group_id="O3" value="-23.04" spread="13.57"/>
                    <measurement group_id="O4" value="-25.20" spread="13.91"/>
                    <measurement group_id="O5" value="-26.77" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.92" spread="15.76"/>
                    <measurement group_id="O2" value="-24.95" spread="12.77"/>
                    <measurement group_id="O3" value="-18.76" spread="16.83"/>
                    <measurement group_id="O4" value="-22.38" spread="15.91"/>
                    <measurement group_id="O5" value="-24.85" spread="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Score &lt;= 2.8 at Week 12</title>
        <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8. Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Score &lt;= 2.8 at Week 12</title>
          <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8. Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="9.9"/>
                    <measurement group_id="O4" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving CDAI Score &lt;= 2.8 Through Week 52</title>
        <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving CDAI Score &lt;= 2.8 Through Week 52</title>
          <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="6.4"/>
                    <measurement group_id="O5" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="17.4"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="10.9"/>
                    <measurement group_id="O5" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="7.5"/>
                    <measurement group_id="O4" value="15.6"/>
                    <measurement group_id="O5" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="27.0"/>
                    <measurement group_id="O3" value="14.6"/>
                    <measurement group_id="O4" value="17.4"/>
                    <measurement group_id="O5" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="16.2"/>
                    <measurement group_id="O4" value="13.3"/>
                    <measurement group_id="O5" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="26.7"/>
                    <measurement group_id="O3" value="18.9"/>
                    <measurement group_id="O4" value="7.0"/>
                    <measurement group_id="O5" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="29.1"/>
                    <measurement group_id="O3" value="13.2"/>
                    <measurement group_id="O4" value="21.4"/>
                    <measurement group_id="O5" value="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="36.5"/>
                    <measurement group_id="O3" value="25.7"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="34.5"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="27.2"/>
                    <measurement group_id="O3" value="22.9"/>
                    <measurement group_id="O4" value="18.4"/>
                    <measurement group_id="O5" value="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="20.9"/>
                    <measurement group_id="O4" value="17.0"/>
                    <measurement group_id="O5" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 12</title>
        <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 12</title>
          <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="13.42"/>
                    <measurement group_id="O2" value="-14.91" spread="13.46"/>
                    <measurement group_id="O3" value="-19.20" spread="11.04"/>
                    <measurement group_id="O4" value="-20.74" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean</param_type>
            <param_value>-8.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.19</ci_lower_limit>
            <ci_upper_limit>-5.20</ci_upper_limit>
            <estimate_desc>Based on ANCOVA Model: CDAI Change = Treatment + Baseline CDAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean</param_type>
            <param_value>-12.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.96</ci_lower_limit>
            <ci_upper_limit>-9.71</ci_upper_limit>
            <estimate_desc>Based on ANCOVA Model: CDAI Change = Treatment + Baseline CDAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score Through Week 52</title>
        <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score Through Week 52</title>
          <description>CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.
CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.01" spread="9.47"/>
                    <measurement group_id="O2" value="-11.42" spread="8.99"/>
                    <measurement group_id="O3" value="-5.61" spread="9.16"/>
                    <measurement group_id="O4" value="-7.28" spread="8.76"/>
                    <measurement group_id="O5" value="-15.73" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.74" spread="11.77"/>
                    <measurement group_id="O2" value="-17.06" spread="9.58"/>
                    <measurement group_id="O3" value="-7.29" spread="11.46"/>
                    <measurement group_id="O4" value="-8.35" spread="11.10"/>
                    <measurement group_id="O5" value="-19.31" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.55" spread="12.71"/>
                    <measurement group_id="O2" value="-19.81" spread="11.21"/>
                    <measurement group_id="O3" value="-7.52" spread="13.88"/>
                    <measurement group_id="O4" value="-10.04" spread="11.47"/>
                    <measurement group_id="O5" value="-21.21" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.17" spread="12.81"/>
                    <measurement group_id="O2" value="-20.06" spread="11.91"/>
                    <measurement group_id="O3" value="-14.40" spread="13.13"/>
                    <measurement group_id="O4" value="-17.72" spread="11.75"/>
                    <measurement group_id="O5" value="-22.08" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.51" spread="13.13"/>
                    <measurement group_id="O2" value="-21.55" spread="11.42"/>
                    <measurement group_id="O3" value="-15.08" spread="14.22"/>
                    <measurement group_id="O4" value="-19.31" spread="12.30"/>
                    <measurement group_id="O5" value="-22.92" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.92" spread="12.65"/>
                    <measurement group_id="O2" value="-22.28" spread="11.75"/>
                    <measurement group_id="O3" value="-15.71" spread="13.08"/>
                    <measurement group_id="O4" value="-20.93" spread="12.88"/>
                    <measurement group_id="O5" value="-23.30" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.97" spread="12.06"/>
                    <measurement group_id="O2" value="-23.38" spread="11.76"/>
                    <measurement group_id="O3" value="-16.74" spread="14.06"/>
                    <measurement group_id="O4" value="-21.48" spread="12.70"/>
                    <measurement group_id="O5" value="-24.09" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.52" spread="12.07"/>
                    <measurement group_id="O2" value="-23.30" spread="11.53"/>
                    <measurement group_id="O3" value="-16.46" spread="14.45"/>
                    <measurement group_id="O4" value="-20.17" spread="13.87"/>
                    <measurement group_id="O5" value="-24.25" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.03" spread="12.22"/>
                    <measurement group_id="O2" value="-23.58" spread="11.41"/>
                    <measurement group_id="O3" value="-19.48" spread="12.86"/>
                    <measurement group_id="O4" value="-20.83" spread="13.10"/>
                    <measurement group_id="O5" value="-24.30" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.41" spread="12.12"/>
                    <measurement group_id="O2" value="-23.76" spread="12.03"/>
                    <measurement group_id="O3" value="-19.00" spread="13.77"/>
                    <measurement group_id="O4" value="-21.86" spread="14.11"/>
                    <measurement group_id="O5" value="-24.87" spread="10.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.34" spread="11.43"/>
                    <measurement group_id="O2" value="-23.84" spread="12.25"/>
                    <measurement group_id="O3" value="-21.34" spread="12.56"/>
                    <measurement group_id="O4" value="-22.00" spread="13.79"/>
                    <measurement group_id="O5" value="-24.54" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.11" spread="11.47"/>
                    <measurement group_id="O2" value="-24.50" spread="11.77"/>
                    <measurement group_id="O3" value="-21.58" spread="12.56"/>
                    <measurement group_id="O4" value="-23.20" spread="13.03"/>
                    <measurement group_id="O5" value="-24.96" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.05" spread="11.94"/>
                    <measurement group_id="O2" value="-24.93" spread="11.90"/>
                    <measurement group_id="O3" value="-21.44" spread="12.72"/>
                    <measurement group_id="O4" value="-23.67" spread="13.42"/>
                    <measurement group_id="O5" value="-25.17" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.82" spread="14.69"/>
                    <measurement group_id="O2" value="-23.12" spread="12.04"/>
                    <measurement group_id="O3" value="-17.96" spread="15.14"/>
                    <measurement group_id="O4" value="-21.39" spread="14.85"/>
                    <measurement group_id="O5" value="-23.52" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Arthritis (PGA) at Week 12</title>
        <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Arthritis (PGA) at Week 12</title>
          <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.94" spread="24.85"/>
                    <measurement group_id="O2" value="-27.69" spread="25.39"/>
                    <measurement group_id="O3" value="-34.65" spread="21.19"/>
                    <measurement group_id="O4" value="-37.40" spread="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-15.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.40</ci_lower_limit>
            <ci_upper_limit>-9.00</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: PGA (100 mm VAS) Change = Treatment + Baseline PGA (100 mm VAS) + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-23.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.78</ci_lower_limit>
            <ci_upper_limit>-17.51</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: PGA (100 mm VAS) Change = Treatment + Baseline PGA (100 mm VAS) + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGA Through Week 52</title>
        <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGA Through Week 52</title>
          <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.71" spread="17.32"/>
                    <measurement group_id="O2" value="-19.49" spread="18.14"/>
                    <measurement group_id="O3" value="-8.77" spread="17.97"/>
                    <measurement group_id="O4" value="-12.37" spread="16.60"/>
                    <measurement group_id="O5" value="-27.48" spread="20.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.92" spread="23.49"/>
                    <measurement group_id="O2" value="-30.55" spread="21.05"/>
                    <measurement group_id="O3" value="-11.70" spread="20.42"/>
                    <measurement group_id="O4" value="-16.04" spread="22.64"/>
                    <measurement group_id="O5" value="-33.80" spread="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.91" spread="25.08"/>
                    <measurement group_id="O2" value="-35.53" spread="21.28"/>
                    <measurement group_id="O3" value="-14.85" spread="24.59"/>
                    <measurement group_id="O4" value="-18.99" spread="23.44"/>
                    <measurement group_id="O5" value="-37.99" spread="20.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.84" spread="23.77"/>
                    <measurement group_id="O2" value="-34.68" spread="22.76"/>
                    <measurement group_id="O3" value="-26.10" spread="22.44"/>
                    <measurement group_id="O4" value="-31.35" spread="20.54"/>
                    <measurement group_id="O5" value="-39.20" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.83" spread="24.45"/>
                    <measurement group_id="O2" value="-38.65" spread="21.19"/>
                    <measurement group_id="O3" value="-28.43" spread="22.91"/>
                    <measurement group_id="O4" value="-33.80" spread="21.18"/>
                    <measurement group_id="O5" value="-41.10" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.67" spread="23.23"/>
                    <measurement group_id="O2" value="-38.50" spread="23.05"/>
                    <measurement group_id="O3" value="-30.62" spread="21.72"/>
                    <measurement group_id="O4" value="-37.43" spread="21.86"/>
                    <measurement group_id="O5" value="-41.18" spread="20.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.17" spread="22.57"/>
                    <measurement group_id="O2" value="-39.29" spread="21.74"/>
                    <measurement group_id="O3" value="-31.69" spread="24.41"/>
                    <measurement group_id="O4" value="-37.90" spread="22.50"/>
                    <measurement group_id="O5" value="-41.51" spread="20.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.14" spread="22.04"/>
                    <measurement group_id="O2" value="-40.49" spread="21.08"/>
                    <measurement group_id="O3" value="-30.22" spread="21.37"/>
                    <measurement group_id="O4" value="-37.27" spread="23.10"/>
                    <measurement group_id="O5" value="-41.95" spread="20.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.29" spread="23.55"/>
                    <measurement group_id="O2" value="-40.76" spread="21.04"/>
                    <measurement group_id="O3" value="-35.44" spread="22.26"/>
                    <measurement group_id="O4" value="-38.90" spread="21.79"/>
                    <measurement group_id="O5" value="-41.27" spread="21.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.95" spread="23.16"/>
                    <measurement group_id="O2" value="-41.88" spread="21.29"/>
                    <measurement group_id="O3" value="-36.31" spread="23.59"/>
                    <measurement group_id="O4" value="-38.83" spread="22.58"/>
                    <measurement group_id="O5" value="-42.93" spread="20.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.53" spread="22.64"/>
                    <measurement group_id="O2" value="-42.16" spread="21.19"/>
                    <measurement group_id="O3" value="-38.01" spread="23.72"/>
                    <measurement group_id="O4" value="-37.74" spread="23.46"/>
                    <measurement group_id="O5" value="-42.65" spread="20.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.29" spread="22.29"/>
                    <measurement group_id="O2" value="-43.41" spread="20.74"/>
                    <measurement group_id="O3" value="-39.09" spread="20.99"/>
                    <measurement group_id="O4" value="-41.99" spread="22.00"/>
                    <measurement group_id="O5" value="-43.71" spread="20.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.85" spread="23.45"/>
                    <measurement group_id="O2" value="-44.02" spread="22.47"/>
                    <measurement group_id="O3" value="-39.43" spread="21.85"/>
                    <measurement group_id="O4" value="-43.24" spread="24.17"/>
                    <measurement group_id="O5" value="-44.11" spread="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.09" spread="25.92"/>
                    <measurement group_id="O2" value="-40.56" spread="22.93"/>
                    <measurement group_id="O3" value="-33.01" spread="25.17"/>
                    <measurement group_id="O4" value="-39.28" spread="24.37"/>
                    <measurement group_id="O5" value="-41.07" spread="22.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subject's SGA at Week 12</title>
        <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subject's SGA at Week 12</title>
          <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.87" spread="25.15"/>
                    <measurement group_id="O2" value="-23.74" spread="32.14"/>
                    <measurement group_id="O3" value="-31.59" spread="27.41"/>
                    <measurement group_id="O4" value="-32.43" spread="27.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-16.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.81</ci_lower_limit>
            <ci_upper_limit>-9.95</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SGA (100 mm VAS) Change = Treatment + Baseline SGA (100 mm VAS) + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-23.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.83</ci_lower_limit>
            <ci_upper_limit>-17.28</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SGA (100 mm VAS) Change = Treatment + Baseline SGA (100 mm VAS) + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGA Through Week 52</title>
        <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGA Through Week 52</title>
          <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.66" spread="24.11"/>
                    <measurement group_id="O2" value="-18.30" spread="24.25"/>
                    <measurement group_id="O3" value="-1.83" spread="18.03"/>
                    <measurement group_id="O4" value="-6.59" spread="21.35"/>
                    <measurement group_id="O5" value="-24.38" spread="25.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.29" spread="30.24"/>
                    <measurement group_id="O2" value="-29.55" spread="26.34"/>
                    <measurement group_id="O3" value="-5.71" spread="22.02"/>
                    <measurement group_id="O4" value="-8.78" spread="21.39"/>
                    <measurement group_id="O5" value="-29.31" spread="26.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.09" spread="31.56"/>
                    <measurement group_id="O2" value="-32.75" spread="27.51"/>
                    <measurement group_id="O3" value="-6.93" spread="22.74"/>
                    <measurement group_id="O4" value="-8.85" spread="27.24"/>
                    <measurement group_id="O5" value="-33.14" spread="27.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.98" spread="30.36"/>
                    <measurement group_id="O2" value="-34.37" spread="28.43"/>
                    <measurement group_id="O3" value="-21.29" spread="24.56"/>
                    <measurement group_id="O4" value="-21.98" spread="25.10"/>
                    <measurement group_id="O5" value="-34.88" spread="25.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.82" spread="32.87"/>
                    <measurement group_id="O2" value="-36.21" spread="26.97"/>
                    <measurement group_id="O3" value="-17.76" spread="26.75"/>
                    <measurement group_id="O4" value="-24.53" spread="24.24"/>
                    <measurement group_id="O5" value="-36.10" spread="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.09" spread="31.93"/>
                    <measurement group_id="O2" value="-37.51" spread="29.32"/>
                    <measurement group_id="O3" value="-25.96" spread="25.72"/>
                    <measurement group_id="O4" value="-25.42" spread="26.02"/>
                    <measurement group_id="O5" value="-37.12" spread="26.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.19" spread="33.76"/>
                    <measurement group_id="O2" value="-37.91" spread="27.72"/>
                    <measurement group_id="O3" value="-25.66" spread="27.71"/>
                    <measurement group_id="O4" value="-26.01" spread="26.63"/>
                    <measurement group_id="O5" value="-37.75" spread="26.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.49" spread="30.49"/>
                    <measurement group_id="O2" value="-38.71" spread="28.92"/>
                    <measurement group_id="O3" value="-27.97" spread="28.37"/>
                    <measurement group_id="O4" value="-26.17" spread="28.46"/>
                    <measurement group_id="O5" value="-38.02" spread="27.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.11" spread="30.55"/>
                    <measurement group_id="O2" value="-39.08" spread="26.81"/>
                    <measurement group_id="O3" value="-31.56" spread="25.36"/>
                    <measurement group_id="O4" value="-26.64" spread="26.00"/>
                    <measurement group_id="O5" value="-37.54" spread="27.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.66" spread="32.19"/>
                    <measurement group_id="O2" value="-40.85" spread="28.00"/>
                    <measurement group_id="O3" value="-30.76" spread="27.65"/>
                    <measurement group_id="O4" value="-28.80" spread="28.13"/>
                    <measurement group_id="O5" value="-38.42" spread="26.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.87" spread="32.36"/>
                    <measurement group_id="O2" value="-39.51" spread="29.51"/>
                    <measurement group_id="O3" value="-36.01" spread="27.49"/>
                    <measurement group_id="O4" value="-28.19" spread="26.52"/>
                    <measurement group_id="O5" value="-39.01" spread="26.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.53" spread="32.53"/>
                    <measurement group_id="O2" value="-41.60" spread="27.74"/>
                    <measurement group_id="O3" value="-34.09" spread="26.60"/>
                    <measurement group_id="O4" value="-31.05" spread="27.81"/>
                    <measurement group_id="O5" value="-39.47" spread="26.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.61" spread="33.45"/>
                    <measurement group_id="O2" value="-41.54" spread="28.60"/>
                    <measurement group_id="O3" value="-32.06" spread="28.15"/>
                    <measurement group_id="O4" value="-32.91" spread="27.33"/>
                    <measurement group_id="O5" value="-40.36" spread="27.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.52" spread="35.62"/>
                    <measurement group_id="O2" value="-38.84" spread="29.05"/>
                    <measurement group_id="O3" value="-26.80" spread="30.15"/>
                    <measurement group_id="O4" value="-28.71" spread="27.54"/>
                    <measurement group_id="O5" value="-37.09" spread="27.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subject's Assessment of Pain at Week 12</title>
        <description>The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subject's Assessment of Pain at Week 12</title>
          <description>The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.64" spread="24.61"/>
                    <measurement group_id="O2" value="-23.78" spread="30.75"/>
                    <measurement group_id="O3" value="-30.65" spread="27.91"/>
                    <measurement group_id="O4" value="-30.82" spread="27.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-17.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.36</ci_lower_limit>
            <ci_upper_limit>-10.81</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SGA of pain (100 mm VAS) Change = Treatment + Baseline SGA of pain (100 mm VAS) + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-23.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.24</ci_lower_limit>
            <ci_upper_limit>-17.57</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SGA of pain (100 mm VAS) Change = Treatment + Baseline SGA of pain (100 mm VAS) + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subject's Assessment of Pain Through Week 52</title>
        <description>The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subject's Assessment of Pain Through Week 52</title>
          <description>The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.80" spread="29.58"/>
                    <measurement group_id="O2" value="-18.36" spread="24.49"/>
                    <measurement group_id="O3" value="-2.00" spread="18.75"/>
                    <measurement group_id="O4" value="-8.23" spread="25.32"/>
                    <measurement group_id="O5" value="-22.24" spread="25.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.45" spread="31.06"/>
                    <measurement group_id="O2" value="-29.58" spread="26.18"/>
                    <measurement group_id="O3" value="-4.11" spread="21.26"/>
                    <measurement group_id="O4" value="-9.17" spread="22.75"/>
                    <measurement group_id="O5" value="-27.43" spread="26.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.02" spread="30.64"/>
                    <measurement group_id="O2" value="-31.83" spread="28.13"/>
                    <measurement group_id="O3" value="-5.40" spread="24.28"/>
                    <measurement group_id="O4" value="-9.15" spread="25.80"/>
                    <measurement group_id="O5" value="-31.37" spread="27.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.58" spread="31.83"/>
                    <measurement group_id="O2" value="-34.41" spread="27.22"/>
                    <measurement group_id="O3" value="-20.93" spread="25.76"/>
                    <measurement group_id="O4" value="-21.20" spread="23.95"/>
                    <measurement group_id="O5" value="-32.48" spread="26.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.68" spread="32.42"/>
                    <measurement group_id="O2" value="-35.83" spread="28.40"/>
                    <measurement group_id="O3" value="-16.21" spread="28.27"/>
                    <measurement group_id="O4" value="-24.63" spread="26.52"/>
                    <measurement group_id="O5" value="-34.76" spread="26.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.78" spread="32.23"/>
                    <measurement group_id="O2" value="-37.78" spread="28.87"/>
                    <measurement group_id="O3" value="-22.64" spread="26.09"/>
                    <measurement group_id="O4" value="-26.51" spread="25.46"/>
                    <measurement group_id="O5" value="-35.45" spread="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.66" spread="31.61"/>
                    <measurement group_id="O2" value="-36.48" spread="29.18"/>
                    <measurement group_id="O3" value="-22.63" spread="28.92"/>
                    <measurement group_id="O4" value="-24.93" spread="26.19"/>
                    <measurement group_id="O5" value="-36.23" spread="27.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.15" spread="30.84"/>
                    <measurement group_id="O2" value="-37.65" spread="28.66"/>
                    <measurement group_id="O3" value="-25.53" spread="27.07"/>
                    <measurement group_id="O4" value="-27.09" spread="26.20"/>
                    <measurement group_id="O5" value="-37.20" spread="27.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.44" spread="30.76"/>
                    <measurement group_id="O2" value="-38.48" spread="27.27"/>
                    <measurement group_id="O3" value="-28.38" spread="25.68"/>
                    <measurement group_id="O4" value="-26.79" spread="25.38"/>
                    <measurement group_id="O5" value="-36.31" spread="26.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.06" spread="31.74"/>
                    <measurement group_id="O2" value="-40.67" spread="27.68"/>
                    <measurement group_id="O3" value="-26.65" spread="28.10"/>
                    <measurement group_id="O4" value="-29.48" spread="26.77"/>
                    <measurement group_id="O5" value="-36.45" spread="26.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.59" spread="30.82"/>
                    <measurement group_id="O2" value="-38.76" spread="29.25"/>
                    <measurement group_id="O3" value="-32.32" spread="27.16"/>
                    <measurement group_id="O4" value="-28.55" spread="25.32"/>
                    <measurement group_id="O5" value="-36.24" spread="25.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.87" spread="31.77"/>
                    <measurement group_id="O2" value="-40.27" spread="28.71"/>
                    <measurement group_id="O3" value="-31.57" spread="27.05"/>
                    <measurement group_id="O4" value="-30.73" spread="27.45"/>
                    <measurement group_id="O5" value="-37.03" spread="26.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.24" spread="34.91"/>
                    <measurement group_id="O2" value="-42.01" spread="28.18"/>
                    <measurement group_id="O3" value="-29.57" spread="26.98"/>
                    <measurement group_id="O4" value="-32.11" spread="27.54"/>
                    <measurement group_id="O5" value="-38.47" spread="26.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.49" spread="34.27"/>
                    <measurement group_id="O2" value="-38.03" spread="29.14"/>
                    <measurement group_id="O3" value="-24.18" spread="28.11"/>
                    <measurement group_id="O4" value="-28.51" spread="27.74"/>
                    <measurement group_id="O5" value="-35.47" spread="27.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Withdrew Due to Lack of Efficacy</title>
        <description>The number of participants who withdrew due to lack of efficacy up to week 12 was calculated.</description>
        <time_frame>Up to week 12</time_frame>
        <population>Initial Randomization Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Withdrew Due to Lack of Efficacy</title>
          <description>The number of participants who withdrew due to lack of efficacy up to week 12 was calculated.</description>
          <population>Initial Randomization Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>No Multiplicity Adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>No Multiplicity Adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12</title>
        <description>The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12</title>
          <description>The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.55"/>
                    <measurement group_id="O2" value="-0.28" spread="0.55"/>
                    <measurement group_id="O3" value="-0.37" spread="0.50"/>
                    <measurement group_id="O4" value="-0.39" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: HAQ-DI Change = Treatment + Baseline HAQ-DI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea., and Taiwan)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: HAQ-DI Change = Treatment + Baseline HAQ-DI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea., and Taiwan)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI Through Week 52</title>
        <description>The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI Through Week 52</title>
          <description>The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.</description>
          <population>FAS, number of participants with available data at each study visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.35"/>
                    <measurement group_id="O2" value="-0.19" spread="0.40"/>
                    <measurement group_id="O3" value="-0.04" spread="0.32"/>
                    <measurement group_id="O4" value="0.01" spread="0.38"/>
                    <measurement group_id="O5" value="-0.24" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.48"/>
                    <measurement group_id="O2" value="-0.31" spread="0.48"/>
                    <measurement group_id="O3" value="-0.07" spread="0.45"/>
                    <measurement group_id="O4" value="0.02" spread="0.39"/>
                    <measurement group_id="O5" value="-0.35" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.55"/>
                    <measurement group_id="O2" value="-0.38" spread="0.50"/>
                    <measurement group_id="O3" value="-0.09" spread="0.55"/>
                    <measurement group_id="O4" value="0.03" spread="0.50"/>
                    <measurement group_id="O5" value="-0.39" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.58"/>
                    <measurement group_id="O2" value="-0.41" spread="0.48"/>
                    <measurement group_id="O3" value="-0.21" spread="0.49"/>
                    <measurement group_id="O4" value="-0.12" spread="0.48"/>
                    <measurement group_id="O5" value="-0.44" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.56"/>
                    <measurement group_id="O2" value="-0.46" spread="0.53"/>
                    <measurement group_id="O3" value="-0.22" spread="0.58"/>
                    <measurement group_id="O4" value="-0.21" spread="0.47"/>
                    <measurement group_id="O5" value="-0.46" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.58"/>
                    <measurement group_id="O2" value="-0.46" spread="0.53"/>
                    <measurement group_id="O3" value="-0.33" spread="0.59"/>
                    <measurement group_id="O4" value="-0.26" spread="0.45"/>
                    <measurement group_id="O5" value="-0.47" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.58"/>
                    <measurement group_id="O2" value="-0.49" spread="0.59"/>
                    <measurement group_id="O3" value="-0.33" spread="0.53"/>
                    <measurement group_id="O4" value="-0.23" spread="0.49"/>
                    <measurement group_id="O5" value="-0.47" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.56"/>
                    <measurement group_id="O2" value="-0.50" spread="0.54"/>
                    <measurement group_id="O3" value="-0.36" spread="0.54"/>
                    <measurement group_id="O4" value="-0.29" spread="0.46"/>
                    <measurement group_id="O5" value="-0.47" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.56"/>
                    <measurement group_id="O2" value="-0.50" spread="0.58"/>
                    <measurement group_id="O3" value="-0.36" spread="0.51"/>
                    <measurement group_id="O4" value="-0.25" spread="0.52"/>
                    <measurement group_id="O5" value="-0.47" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.60"/>
                    <measurement group_id="O2" value="-0.51" spread="0.57"/>
                    <measurement group_id="O3" value="-0.35" spread="0.50"/>
                    <measurement group_id="O4" value="-0.28" spread="0.47"/>
                    <measurement group_id="O5" value="-0.48" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.58"/>
                    <measurement group_id="O2" value="-0.51" spread="0.58"/>
                    <measurement group_id="O3" value="-0.42" spread="0.63"/>
                    <measurement group_id="O4" value="-0.27" spread="0.51"/>
                    <measurement group_id="O5" value="-0.49" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.56"/>
                    <measurement group_id="O2" value="-0.52" spread="0.57"/>
                    <measurement group_id="O3" value="-0.40" spread="0.59"/>
                    <measurement group_id="O4" value="-0.31" spread="0.50"/>
                    <measurement group_id="O5" value="-0.51" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.57"/>
                    <measurement group_id="O2" value="-0.54" spread="0.56"/>
                    <measurement group_id="O3" value="-0.46" spread="0.57"/>
                    <measurement group_id="O4" value="-0.29" spread="0.51"/>
                    <measurement group_id="O5" value="-0.51" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.60"/>
                    <measurement group_id="O2" value="-0.50" spread="0.57"/>
                    <measurement group_id="O3" value="-0.37" spread="0.64"/>
                    <measurement group_id="O4" value="-0.24" spread="0.50"/>
                    <measurement group_id="O5" value="-0.47" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 m</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="12.20"/>
                    <measurement group_id="O2" value="8.36" spread="14.05"/>
                    <measurement group_id="O3" value="8.81" spread="10.54"/>
                    <measurement group_id="O4" value="8.53" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>6.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.69</ci_lower_limit>
            <ci_upper_limit>10.05</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SF-36v2 Change = Treatment + Baseline SF-36v2 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>6.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.11</ci_lower_limit>
            <ci_upper_limit>9.85</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SF-36v2 Change = Treatment + Baseline SF-36v2 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the SF-36 questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.New Group 3 Description</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the SF-36 questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="10.21"/>
                    <measurement group_id="O2" value="3.20" spread="10.49"/>
                    <measurement group_id="O3" value="6.10" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" spread="10.98"/>
                    <measurement group_id="O2" value="6.78" spread="9.99"/>
                    <measurement group_id="O3" value="7.35" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.93" spread="12.38"/>
                    <measurement group_id="O2" value="9.63" spread="10.33"/>
                    <measurement group_id="O3" value="8.40" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.85" spread="12.79"/>
                    <measurement group_id="O2" value="10.95" spread="12.04"/>
                    <measurement group_id="O3" value="10.28" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.07" spread="12.41"/>
                    <measurement group_id="O2" value="9.88" spread="12.51"/>
                    <measurement group_id="O3" value="11.18" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="8.65"/>
                    <measurement group_id="O2" value="2.70" spread="7.59"/>
                    <measurement group_id="O3" value="3.69" spread="8.23"/>
                    <measurement group_id="O4" value="3.23" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>2.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>4.87</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SF-36v2 Change = Treatment + Baseline SF-36v2 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>3.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>5.19</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SF-36v2 Change = Treatment + Baseline SF-36v2 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the SF-36 questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the SF-36 questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="7.19"/>
                    <measurement group_id="O2" value="1.72" spread="7.58"/>
                    <measurement group_id="O3" value="2.85" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="7.39"/>
                    <measurement group_id="O2" value="3.55" spread="9.08"/>
                    <measurement group_id="O3" value="3.56" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="7.53"/>
                    <measurement group_id="O2" value="4.01" spread="8.17"/>
                    <measurement group_id="O3" value="3.63" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="8.07"/>
                    <measurement group_id="O2" value="3.52" spread="8.14"/>
                    <measurement group_id="O3" value="3.80" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" spread="8.17"/>
                    <measurement group_id="O2" value="4.39" spread="8.08"/>
                    <measurement group_id="O3" value="3.79" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="15.12"/>
                    <measurement group_id="O2" value="1.24" spread="14.40"/>
                    <measurement group_id="O3" value="7.04" spread="14.56"/>
                    <measurement group_id="O4" value="7.16" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.210</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>2.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>5.83</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SF-36v2 Change = Treatment + Baseline SF-36v2 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>6.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.74</ci_lower_limit>
            <ci_upper_limit>9.71</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: SF-36v2 Change = Treatment + Baseline SF-36v2 + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the SF-36 questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the SF-36 questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="12.75"/>
                    <measurement group_id="O2" value="4.27" spread="12.02"/>
                    <measurement group_id="O3" value="4.06" spread="13.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="13.23"/>
                    <measurement group_id="O2" value="5.96" spread="14.60"/>
                    <measurement group_id="O3" value="6.51" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="14.33"/>
                    <measurement group_id="O2" value="7.82" spread="14.66"/>
                    <measurement group_id="O3" value="7.49" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="14.21"/>
                    <measurement group_id="O2" value="8.78" spread="14.20"/>
                    <measurement group_id="O3" value="7.31" spread="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="15.12"/>
                    <measurement group_id="O2" value="9.15" spread="13.39"/>
                    <measurement group_id="O3" value="8.36" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percent Work Time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="25.76"/>
                    <measurement group_id="O2" value="-2.14" spread="18.47"/>
                    <measurement group_id="O3" value="-6.80" spread="19.40"/>
                    <measurement group_id="O4" value="-5.60" spread="20.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-8.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.11</ci_lower_limit>
            <ci_upper_limit>-1.00</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-10.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.88</ci_lower_limit>
            <ci_upper_limit>-2.47</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Work Time Missed Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).</description>
        <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Work Time Missed Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).</description>
          <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
          <units>Percent Work Time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="20.13"/>
                    <measurement group_id="O2" value="-6.35" spread="15.94"/>
                    <measurement group_id="O3" value="-3.71" spread="17.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="16.15"/>
                    <measurement group_id="O2" value="-6.10" spread="19.30"/>
                    <measurement group_id="O3" value="-4.33" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="18.13"/>
                    <measurement group_id="O2" value="-6.69" spread="19.78"/>
                    <measurement group_id="O3" value="-4.73" spread="18.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="24.48"/>
                    <measurement group_id="O2" value="-6.46" spread="20.29"/>
                    <measurement group_id="O3" value="-5.03" spread="18.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.76" spread="22.20"/>
                    <measurement group_id="O2" value="-6.35" spread="16.57"/>
                    <measurement group_id="O3" value="-4.52" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Impairment While Working at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Impairment While Working at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percent Impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="30.15"/>
                    <measurement group_id="O2" value="-13.04" spread="30.45"/>
                    <measurement group_id="O3" value="-16.12" spread="31.94"/>
                    <measurement group_id="O4" value="-24.43" spread="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-20.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.44</ci_lower_limit>
            <ci_upper_limit>-10.89</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-22.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.06</ci_lower_limit>
            <ci_upper_limit>-11.97</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Impairment While Working Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.</description>
        <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Impairment While Working Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.</description>
          <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
          <units>percent impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.42" spread="22.28"/>
                    <measurement group_id="O2" value="-6.46" spread="27.48"/>
                    <measurement group_id="O3" value="-18.33" spread="26.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.31" spread="26.10"/>
                    <measurement group_id="O2" value="-15.42" spread="27.75"/>
                    <measurement group_id="O3" value="-20.52" spread="25.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.33" spread="30.96"/>
                    <measurement group_id="O2" value="-19.77" spread="31.66"/>
                    <measurement group_id="O3" value="-24.11" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.35" spread="34.63"/>
                    <measurement group_id="O2" value="-25.85" spread="28.10"/>
                    <measurement group_id="O3" value="-29.53" spread="26.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.79" spread="36.27"/>
                    <measurement group_id="O2" value="-23.89" spread="30.55"/>
                    <measurement group_id="O3" value="-31.36" spread="31.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent Overall Work Impairment at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent Overall Work Impairment at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percent iImpairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" spread="30.49"/>
                    <measurement group_id="O2" value="-12.20" spread="31.39"/>
                    <measurement group_id="O3" value="-18.68" spread="33.81"/>
                    <measurement group_id="O4" value="-24.68" spread="26.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-20.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.38</ci_lower_limit>
            <ci_upper_limit>-10.06</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Covariance model</method>
            <method_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</method_desc>
            <param_type>LS mean</param_type>
            <param_value>-23.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.16</ci_lower_limit>
            <ci_upper_limit>-13.17</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].</description>
        <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].</description>
          <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
          <units>Percent Impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.72" spread="21.61"/>
                    <measurement group_id="O2" value="-8.67" spread="28.20"/>
                    <measurement group_id="O3" value="-18.20" spread="26.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.16" spread="27.22"/>
                    <measurement group_id="O2" value="-17.44" spread="29.05"/>
                    <measurement group_id="O3" value="-20.94" spread="25.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.16" spread="32.11"/>
                    <measurement group_id="O2" value="-22.84" spread="33.22"/>
                    <measurement group_id="O3" value="-25.35" spread="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.48" spread="34.87"/>
                    <measurement group_id="O2" value="-28.68" spread="29.66"/>
                    <measurement group_id="O3" value="-30.12" spread="28.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.53" spread="35.95"/>
                    <measurement group_id="O2" value="-24.75" spread="31.45"/>
                    <measurement group_id="O3" value="-32.18" spread="31.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Activity Impairment at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.</description>
        <time_frame>Baseline and Week 12/ET</time_frame>
        <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Activity Impairment at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.</description>
          <population>FAS, number of participants with both baseline and available post-baseline data up to week 12. LOCF was used.</population>
          <units>Percent Impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.65" spread="26.39"/>
                    <measurement group_id="O2" value="-19.61" spread="29.62"/>
                    <measurement group_id="O3" value="-24.65" spread="28.27"/>
                    <measurement group_id="O4" value="-26.40" spread="24.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-17.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.00</ci_lower_limit>
            <ci_upper_limit>-10.61</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment. Etanercept was open-label reference group and it was not included in statistical test.</p_value_desc>
            <method>Covariance model</method>
            <param_type>LS mean</param_type>
            <param_value>-20.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.59</ci_lower_limit>
            <ci_upper_limit>-14.24</ci_upper_limit>
            <estimate_desc>Based on analysis of covariance model: WPAI Change = Treatment + Baseline WPAI + the prior biologic-DMARD-IR (No, Yes) + concomitant DMARD use (No, Yes) + study region (Japan, Korea, and Taiwan).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Activity Impairment Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.</description>
        <time_frame>Baseline and Week 4, 8, 12, 28, and 52</time_frame>
        <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Activity Impairment Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.</description>
          <population>FAS, number of participants with available data at each study visit. The focus of data collection after Week 12 for participants transitioned from Placebo to Peficitinib was safety. Long term efficacy was not evaluated by the WPAI questionnaire for them. These assessments were only conducted at Weeks 28 and 52 after transitioning to Peficitinib.</population>
          <units>percent impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.92" spread="24.75"/>
                    <measurement group_id="O2" value="-11.30" spread="21.82"/>
                    <measurement group_id="O3" value="-17.90" spread="23.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.10" spread="26.89"/>
                    <measurement group_id="O2" value="-23.64" spread="26.05"/>
                    <measurement group_id="O3" value="-25.33" spread="23.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.47" spread="29.53"/>
                    <measurement group_id="O2" value="-26.74" spread="28.48"/>
                    <measurement group_id="O3" value="-27.33" spread="23.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.18" spread="31.40"/>
                    <measurement group_id="O2" value="-30.00" spread="27.80"/>
                    <measurement group_id="O3" value="-30.34" spread="26.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.17" spread="30.01"/>
                    <measurement group_id="O2" value="-34.07" spread="27.69"/>
                    <measurement group_id="O3" value="-31.79" spread="26.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events During the First 12 Weeks</title>
        <description>Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
        <time_frame>Week 0 to Week 12</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events During the First 12 Weeks</title>
          <description>Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
          <population>SAF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ Grade 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs leading to discont.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events From Week 12</title>
        <description>Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
        <time_frame>Week 12 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Etanercept</title>
            <description>Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events From Week 12</title>
          <description>Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
          <population>SAF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ Grade 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs leading to discont.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 0 to week 12, and from week 12 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study.</time_frame>
      <desc>The safety analysis set (SAF) consisted of all participants who received at least one dose of study drugs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Weeks 0-12: Placebo</title>
          <description>Participants were assigned to receive placebo to peficitinib once a day until week 12.</description>
        </group>
        <group group_id="E2">
          <title>Weeks 0-12: Peficitinib 100 mg</title>
          <description>Participants were assigned to receive peficitinib 100 mg/day until 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Weeks 0-12: Peficitinib 150 mg</title>
          <description>Participants were assigned to receive peficitinib 150 mg/day until 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Weeks 0-12: Etanercept</title>
          <description>Participants were administered 50 mg of subcutaneous etanercept once weekly until 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Weeks 12-52: Peficitinib 100 mg</title>
          <description>Participants were assigned to receive peficitinib 100 mg/day until 12 weeks and from week 12 to week 52.</description>
        </group>
        <group group_id="E6">
          <title>Weeks 12-52: Peficitinib 150 mg</title>
          <description>Participants were assigned to receive peficitinib 150 mg/day until 12 weeks and from week 12 to week 52.</description>
        </group>
        <group group_id="E7">
          <title>Weeks 12-52: Placebo / Peficitinib 100 mg</title>
          <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 100 mg/day from week 12 to week 52.</description>
        </group>
        <group group_id="E8">
          <title>Weeks 12-52: Placebo / Peficitinib 150 mg</title>
          <description>Participants were assigned to receive placebo to peficitinib once a day until week 12 and peficitinib 150 mg/day from week 12 to week 52.</description>
        </group>
        <group group_id="E9">
          <title>Weeks 12-52: Etanercept</title>
          <description>Participants were administered 50 mg of subcutaneous etanercept once weekly until 12 weeks and from week 12 to week 52.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypereosinophilic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bronchoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="200"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="47"/>
                <counts group_id="E9" subjects_affected="94" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="77" subjects_affected="25" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="63" subjects_affected="9" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="200"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="6" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E9" events="8" subjects_affected="8" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="102"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="200"/>
                <counts group_id="E5" events="30" subjects_affected="21" subjects_at_risk="96"/>
                <counts group_id="E6" events="21" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E7" events="18" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E8" events="11" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E9" events="77" subjects_affected="49" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E5" events="11" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="12" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="10" subjects_affected="8" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E9" events="8" subjects_affected="8" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="10" subjects_affected="9" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The focus of data collection after Week 12 for participants who transitioned from Placebo to Peficitinib was safety. Efficacy was not evaluated by the SF-36 and WPAI questionnaire after Week 12 for participants first assigned to placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Astellas Pharma Inc.</organization>
      <phone>+81 3-3244-0512</phone>
      <email>astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

